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Abstract 
 
It has previously been demonstrated that the biological incorporation and chemical 
modification of cysteine residues within the active site of the aldolase N-acetylneuraminic acid 
lyase (NAL) can lead to active chemically modified NAL variants. 
This thesis reports the exploitation of this joint chemical/biological method in the 
incorporation of several unnatural amino acids into the active site of Staphylococcus aureus 
NAL (SaNAL). This work was performed in an attempt to broaden the substrate specificity of 
the protein, to allow for the catalysis of the retro-aldol reaction of analogues of N-
acetylneuraminic acid (the natural substrate of NAL).  
This method was used to incorporate a range of unnatural amino acids into the active site and 
kinetic parameters of these proteins were assessed with several varied N-acetylneuraminic 
acid analogues: 
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The residues F190 and E192 of SaNAL were chosen for chemical modification as they have 
previously been shown to be important for the catalytic function of the protein. 
A coupled enzyme assay was used to assess the kinetic parameters of the chemically modified 
variants of SaNAL with the analogues of N-acetylneuraminic acid. As a result, it was found that 
a range of chemically modified amino acids at position 192 of SaNAL would allow for improved 
specific activity (kcat/KM) of the retro aldol reaction with the substrate  DPAH, when compared 
to wild-type SaNAL with DPAH. An interesting relationship was also observed between the 
functionality of chemically modified amino acids at position 190 and the specific activity of the 
resulting protein in the retro-aldol of the substrate N-acetylneuraminic acid. 
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S
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Introduction 
 
1.1 Enzymatic Catalysis 
 
Enzymes are highly selective and efficient catalysts essential to life, some capable of increasing 
the rate of reactions up to 1018-fold.1,2 Catalysis can be achieved by re-orientation of 
substrates, the formation of reactive intermediates and reduction of the transition state 
energy barrier.3 Enzymes can also maintain their catalytic activity with substrate 
concentrations in the range of nanomolar to micromolar; much lower than those typically used 
in synthetic chemistry (micromolar to molar).4 Enzymes have the ability to hold the substrates 
in the correct conformation via specific interactions between substrates and active site amino 
acid residues.5 Enzyme-substrate interactions include covalent bonding, hydrogen bonding, 
and hydrophobic interactions.6 Residues within the active site perform roles such as donating 
or accepting protons, facilitating metal coordination, and stabilising reactive intermediates. 
Generally, enzyme mechanisms involve the binding of substrate(s) within the active site, the 
enzyme-substrate complex undergoing a chemical reaction, and then the immediate release of 
the newly formed molecule(s).7 Enzyme-catalysed reactions are often reversible, and the rate 
determining step of an enzyme reaction is frequently the diffusion of the product from the 
enzyme.6 Enzymes are often highly specific and perform their catalytic function with a small 
range of substrates.6 
 
1.1.1 Serine Proteases 
 
Proteases are enzymes capable of cleaving amide bonds within proteins. Serine proteases 
make up one third of all proteases8,9 and provide a useful example of enzyme catalysis, 
illustrating many of the hallmarks of enzymatic catalysis. Serine proteases have a triad of 
catalytic enzymatic residues – serine, histidine and aspartic acid – which are intimately 
involved in the catalysis, whilst other residues hold the substrate in place through non-
covalent interactions (Scheme 1).10 
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Scheme 1 | General mechanism for chymotrypsin-like serine proteases, adapted from 8,11. 
The protein substrate (red) is bound by hydrogen bonding with Ser195 and with Gly193, whilst 
the His57 molecule acts as a general base, stabilised by Asp102. The residues are numbered 
according to Bos taurus chymotrypsinogen.   
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Residues Ser195 and Gly193 (numbered according to Bos taurus chymotrypsinogen) hold the 
substrate in place via N-H hydrogen bonding, and in doing so they aid the formation of an 
oxyanion. These interactions facilitate the cleavage of a functional group which is usually very 
unreactive.8 The catalytic triad assists the cleavage because serine alone, with a pKa of ~13, is 
not ionised under physiological conditions. This catalytic triad is composed of His57, Asp102 
and Ser195. His195 (pKa ~7) is stabilised via electrostatic interactions with the deprotonated 
Asp102 and is therefore able to deprotonate Ser195. This deprotonation leaves Ser195 suitably 
nucleophilic to attack the polarised amide bond of the protein substrate.6,8  
 
1.1.2 Aldolase Enzymes. 
 
The most relevant family of enzymes to this project are the aldolases, enzymes which catalyse 
aldol reactions. There are two types of aldolase enzymes which are classified by their 
mechanism. The mechanism of Class I aldolases proceeds via an enamine from a Schiff base 
formed between a catalytic lysine residue and the relevant substrate, which then performs the 
aldol reaction by attacking an aldehyde (Scheme 2).12 The mechanism of Class II aldolases, 
however, proceeds via an enolate, stabilised by the coordination of a divalent metal, allowing 
the aldol reaction to occur (Scheme 3).13 
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Scheme 2 | The general mechanism for a Class I aldolase, illustrated with fructose-1,6-
biphosphate (FBP) aldolase. The substrates are dihydroxyacetone phosphate (DHAP) and D-
glyceraldehyde 3-phosphate. The catalytic lysine residue forms a Schiff base with DHAP which 
leads to the formation of the reactive enamine which then attacks the glyceraldehyde 
molecule. Mechanism adapted from 14. 
 
Scheme 3 | The general mechanism for a Class II aldolase exemplified using fructose-1,6-
biphosphate (FBP) aldolase. The substrates are dihydroxyacetone phosphate (DHAP) and D-
glyceraldehyde 3-phosphate. A glutamate residue is able to deprotonate the DHAP, forming an 
enediolate intermediate stabilised by a metal ion held by the enzyme (E). Mechanism adapted 
from 14.  
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1.1.3 Catalytic mechanism of N-acetylneuraminic acid lyase (NAL) 
 
This project will focus on the aldolase N-acetylneuraminic acid lyase (NAL), a Class I aldolase 
which catalyses the reversible aldol condensation between N-acetyl-D-mannosamine 
(ManNAc) and pyruvate to yield the sialic acid, N-acetylneuraminic acid (Neu5Ac) (Scheme 4). 
NAL has commercial importance as it provides an efficient way to synthesise pure N-
acetylneuraminic acid, a key intermediate in the synthesis of the influenza uptake inhibitor, 
Relenza.14b  
 
Scheme 4 | The reversible aldol reaction catalysed by the enzyme NAL. ManNAc and Neu5Ac 
are represented in the open chain form for clarity.  
 
In-depth characterisation of the mechanism of this aldolase has been achieved through 
mutagenesis, crystal structure analysis and quantum mechanics molecular modelling 
(QM/MM) calculations.15,16 The enzyme catalyses a bi-uni ordered condensation reaction in 
which pyruvate first binds to a catalytic lysine residue to form the reactive Schiff base. The 
substrate ManNAc is recognised by the enzyme through hydrogen bonding from the four 
alcohols of ManNAc to the residues Glu192, Asp191, Ser208 and Gly189 of E. Coli NAL (Figure 
1, numbered according to E. Coli NAL). 
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Figure 1 | Structural insight into E. Coli NAL. A) Hydrogen bond stabilisation to ManNAc is 
achieved through the side chains Glu192, Asp191, and Ser208.  B) Crystal structure of the 
Y137A E. Coli NAL variant (green) covalently bound to full length N-acetylneuraminic acid (pale 
blue). The residues K165, D191, E192 and S208 have been highlighted. Numbering of residues 
is in accordance with E. coli NAL.15,16 
 
The mechanism for the aldol reaction between N-acetyl-D-mannosamine (ManNAc) and 
pyruvate catalysed by NAL is shown in Scheme 5. In the forward direction, the enamine of the 
Schiff base (formed from the attack of pyruvate by Lys165) then undergoes nucleophilic attack 
onto the aldehyde of the substrate ManNAc. The nucleophilic enamine attacks the si face of 
ManNAc to produce the 4S – configured product. The stereoselectivity is achieved through the 
hydrogen bonding between the aldehyde group of ManNAc and the hydroxyl group of each of 
the residues Thr167 and Tyr137. During the forward aldol reaction, ManNAc gains a proton 
from Tyr137. QM/MM calculations suggest that this proton transfer is asynchronous and 
occurs when the distance between the anion of N-acetylneuraminic acid and the proton of 
Tyr137 is 1.7 Å or smaller. The resulting phenolate at residue 137 is stabilised through 
hydrogen bonding from the alcohol groups on Ser47 and Tyr110. The triad of amino acids – 
here, Ser47, Tyr110 and Tyr137 – is a common feature in several enzymes.17-19 Once the 
aldolase reaction is complete, hydrolysis of the Schiff base reveals N-acetylneuraminic acid. 
Site-directed mutagenesis studies complement the QM/MM, as the mutants Y137F and Y137A 
exhibit decreased kinetic parameters.15,16 The mutant Y137F exhibited ~ 0.2 % of activity of E. 
coli NAL with N-acetylneuraminic acid and the variant Y137A exhibited no detectable activity.16 
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Scheme 5 | Mechanism of the forward aldol reaction between the substrates pyruvate and 
ManNAc catalysed by E. coli NAL. Key steps: 1) Lys165 attacks pyruvate, resulting in a Schiff 
base. 2) The Schiff base attacks the si face of the substrate ManNAc which is then protonated 
by Tyr137, stabilised through a triad of residues Tyr137, Ser47 and Tyr110. 3) Hydrolysis of the 
resulting iminium yields N-acetylneuraminic acid.  Figure adapted from 15. 
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1.2 Enzymes with naturally modified catalytic residues 
 
Post-translational modifications are reactions which occur at specific sites within a protein 
once the protein has been expressed. Post-translational modifications are important processes 
which are central to a wide range of critical biological mechanisms.20 The post-translational 
modification of a protein can affect the protein in many ways, including: controlling the 
tertiary structure of a protein, stabilising the protein, and altering the functionality of the 
protein. For instance, lipidation can help orient groups of proteins into the appropriate 
membrane within a cell.21 Post-translational modifications can also act as a switch to turn the 
function of the protein off or on; protein kinases and phosphatases add or remove phosphate 
(respectively) from nucleophilic functional groups such as serine, threonine and tyrosine.20,22,23 
Over two hundred types of post-translational modifications are known and almost all of them 
are catalysed by dedicated enzymes. Only very few proteins undergo automodifications to 
achieve their post-translational modifications, for example green fluorescent protein (GFP).20  
Cofactors are non-peptidic species which aid the catalytic function of a protein. An example of 
this is the zinc ion found in the class II aldolase, discussed in section 1.1.2, Scheme 3.24 There 
are several examples of the covalent incorporation of cofactors into the active site of enzymes 
by post- translational modifications.25-28  The covalently incorporated cofactor can then act as a 
key catalytic group essential to the function of the protein. Often the cofactor will act as an 
electrophile, extending the reactivity of proteins beyond that seen with the canonical twenty 
amino acid side chains.25-28 An example of this is the cofactor involved in the catalytic functions 
of histidine ammonia-lyase and phenylalanine ammonia lyase.27,29 
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1.2.1 Histidine ammonia-lyase and phenylalanine ammonia-lyase 
 
Histidine and phenylalanine ammonia-lyase are enzymes which perform the elimination of 
ammonia from histidine and phenylalanine respectively.27,29 Both histidine ammonia-lyase and 
phenylalanine ammonia-lyase have been found to perform their catalytic functions through a 
covalently bound methylidene-imidazoline cofactor.27   
It has been proposed that the methylidene-imidazoline moiety in histidine ammonia-lyase is 
formed from an autocatalytic cyclic condensation of the amide of residue of Gly144 onto the 
carbonyl of residue of Ala142, followed by the elimination of the alcohol of Ser143 (Scheme 
6).27,30 Throughout this Chapter BH+ represents a general acid and B represents a general base. 
 
Scheme 6 | Proposed mechanism for the post translational formation of a methylidene-
imidazoline cofactor in histidine ammonia-lyase (on the basis of the crystal structure of 
Pseudomonas putida histidine ammonia lyase). The cyclisation involves residues Gly144 and 
Ala142, followed by the elimination of a primary alcohol from Ser143. Mechanism adapted 
from 27,30.  
 
The mechanisms of histidine ammonia-lyase and phenylalanine ammonia-lyase are believed to 
be similar. The proposed mechanism of histidine ammonia-lyase is depicted in Scheme 7.29 The 
reaction begins with the attack of the Michael acceptor of methylidene-imidazoline cofactor by 
the imidazole moiety of histidine (step 1). A proton alpha to the imidazole moiety of histidine 
is then removed by a general base (step 2). The imidazole of histidine then facilitates the 
elimination of ammonia (step 3) and the α,β-unsaturated acid product is released, 
regenerating the methylidene-imidazoline cofactor (step 4).29  
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Scheme 7 | Proposed mechanism of histidine ammonia-lyase adapted from 29. The 
methylidene-imidazoline cofactor acts as an electron sink, facilitating the elimination of 
ammonia. 
 
1.2.2 Histidine decarboxylase 
 
Decarboxylation is a process fundamental to many catabolic and anabolic pathways such as 
glycolysis and the Krebs cycle, providing a source of energy for biological cells and organisms.6 
Broadly speaking, decarboxylases utilise cofactors to facilitate the breakdown of α- and β- keto 
acids, amino acids and carbohydrates. Examples of these cofactors include: thiamine 
pyrophosphate for α-keto acid decarboxylation, and pyridoxal 5’-phosphate for amino acid 
decarboxylation. This is not the case for all decarboxylases, as some obtain their catalytic 
ability through post-translational modification.20,26  
Histidine decarboxylase is an example of an enzyme with a post-translationally modified 
electrophilic pyruvoyl functionality, integral to the catalytic process of the enzyme.30 The 
pyruvoyl functionality is formed from an intramolecular attack on a neighbouring amide by the 
alcohol of a serine residue, followed by cleavage and hydration (Scheme 8). Histidine 
decarboxylase was one of the first pyruvoyl enzymes to be discovered.6,30,31 Other pyruvoyl 
post-translational modifications which catalyse α-decarboxylation of amino acids include S-
adenosylmethionine, phosphatidyl serine, and aspartate α-decarboxylases.6  
11 
 
 
Scheme 8 | Proposed formation of α-ketoamide functionality of histidine decarboxylase, 
initiated by an intramolecular nucleophilic attack by a serine residue. Scheme adapted from 
27. 
Histidine decarboxylase catalyses the breakdown of histidine to histamine and carbon dioxide. 
Scheme 9 shows the proposed mechanism for the cleavage of the carboxylic acid of histidine.27 
The mechanism begins with the amine of histidine attacking the ketone to generate an 
iminium intermediate (steps 1 and 2). In step 3, the carboxylic acid of histidine is cleaved, 
releasing a molecule of CO2. This is facilitated by the unnatural α-ketoamide functionality 
which acts as an electron sink, as well as the proton on the glutamic acid at position 197 
(numbered according to Lactobacillus 30a histidine decarboxylase) providing electrostatic 
destabilisation. In steps 4-6, hydrolysis of the covalent intermediates leads to release of the 
product.27,32 
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Scheme 9 | Proposed histidine decarboxylase mechanism, adapted from 27,33. The post-
translational α-ketoamide acts as an electron sink which facilitates the decarboxylation of 
histidine. (numbered according to Lactobacillus 30a histidine decarboxylase). 
 
Both histidine ammonia-lyase and histidine decarboxylase utilise unnatural amino acids to 
catalyse reactions by acting as an electron sink. Such enzymatic mechanisms would not be 
possible without utilising cofactors or post-translational modifications.  
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1.3 Preparation of proteins containing unnatural amino acids 
 
Chemists and biologists have developed many varied techniques to introduce new 
functionality into proteins with the goal of probing or altering function. The techniques span 
both chemical reactions with amino acid side chains and biological techniques that expand the 
genetic code. Often, the use of both pre- and post-translational modifications are necessary, 
for example, incorporating an amino acid into the genetic code prior to translation and then 
chemically modifying the incorporated amino acid side chain.34  
This section will describe several methods, both chemical and biological, available to 
incorporate unnatural amino acids into proteins. Two commonly used methods of protein 
modification omitted from this section are native chemical ligation 35,36 and also solid phase 
peptide synthesis 37, as generally these techniques are not exploited for the modification of a 
single residue. Chemical ligation is largely exploited for protein-protein coupling,38,39 and solid 
phase peptide synthesis is exploited for the synthesis of relatively short peptide chains.37 These 
two techniques have been widely reviewed elsewhere.36,37 
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1.3.1 Schultz’s methodology for the incorporation of unnatural amino acids 
 
Over the past two decades Schultz and co-workers have developed methods to expand the 
genetic code. The method involves manipulating one of three stop codons (usually amber) into 
coding for the incorporation of an unnatural amino acid.40-43 Inspiration for this may have 
come from the rare 21st and 22nd amino acids, selenocysteine and pyrrolysine, found in natural 
species and coded by the two stop codons amber and opal respectively.44-46 The method relies 
on creating a ‘codon-tRNA pair’ with a corresponding tRNA synthetase which, during the 
process of translation, will insert an unnatural amino acid when confronted with an amber 
stop codon.40,47 Crucially, the new tRNA must not act as a substrate for any other aminoacyl 
tRNA synthetase. The synthetase which is compatible with the unnatural amino acid must also 
be very selective. Many novel amino acids have been incorporated in this way, especially 
substituted phenylalanine analogues. Figure 2 shows a few examples of unnatural amino acids 
which have been incorporated in this fashion. This method of incorporating unnatural amino 
acids is most frequently used for aromatic residues, though other unnatural residues have also 
been incorporated.48   
H2N CO2H
O
H2N CO2H
O
H2N CO2H
N3
H2N CO2H
OO
1 2 3 4  
Figure 2 | Examples of unnatural amino acids which have been successfully added to the 
genetic code.40,47,49,50 A broad range of aromatic amino acids has been incorporated into 
peptides using this technique.48,51,52  
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1.3.2 Chemical modification of nucleophilic amino acid residues 
 
Analogous to post-translational modifications, chemists have been able to develop 
methodologies to allow the chemical modification of specific amino acid side chains within a 
protein.53,54 Several factors need to be taken into account when performing chemical 
modifications of proteins. The reactions must be selective for a specific residue, and reactions 
must be capable of proceeding in a buffered aqueous environment  at relatively mild pH and 
temperature.55 
Nucleophilic residues such as lysine and cysteine can attack electrophiles directly to produce 
unnatural amino acids.53,56,57 As the modifications are made after the protein has been 
expressed, the selectivity depends on the number and accessibility of nucleophilic residues. 
Residues on the surface of proteins are more readily available for chemical reactions than 
those that are buried within the folded protein. Cysteine residues are often utilised due to 
their relatively low occurrence in proteins and also their high nucleophilicity.34 A wide array of 
modifications has been implemented with the aim of altering stability or reactivity, or to probe 
function. Again, the incorporation of the unnatural side chains relies on the tolerance of the 
protein for the incorporated functionality (Scheme 10 and Scheme 11).58,59 Examples of the 
chemical modification of other amino acid side chains include the reactions of tyrosine 
residues with iminium ions,60 cyclisation of arginine  residues by reaction with 2-oxopropanal, 
and reaction of histidine residues  with epoxides.53  
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Scheme 10 | Chemical modifications of lysine residues.59,61 Residue 5 results from 
nucleophilic attack onto the N-hydroxysuccinimide ester 6 and the residue 9 results from 
nucleophilic attack onto the isothiocyanate 8.  
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Scheme 11 | Chemical modifications of cysteine residues.59,61,62 Examples shown are the 
nucleophilic attack onto maleimides, thiosulfonates, vinyl sulfonates and alkylhalides.   
 
There are also several examples of metal-mediated chemical modifications of nucleophilic 
amino acid residues. This includes the iridium-mediated reductive aminations of lysine, π-allyl 
palladium-mediated attack of allylic acetates by tyrosine, and rhodium-mediated carbene 
reactions with tryptophan. Metal-mediated methods for the chemical modification of amino 
acid side chains have been reviewed elsewhere.53 
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1.3.3 Chemical modification to yield dehydroalanine residues, and subsequent reaction 
 
Dehydroalanine residues are known to form naturally within enzymes, such as bacterial 
phosphothreonine lyases via the post-translational oxidative elimination of cysteine or 
serine.63,64 With the ability to act as a Michael acceptor, the dehydroalanine functionality can 
serve as an effective intermediate in the synthesis of unnatural amino acids.65 Selective 
formation of dehydroalanine could therefore be a useful synthetic tool for the incorporation of 
unnatural amino acids (Scheme 12).    
 
R'HN
NHR''
SePh
oxidative
elimination R'HN
NHR'' RSH
R'HN
NHR''
SR
amino acid inserted via
Schultz methodology.
19
20
21
O O O
 
Scheme 12 | Michael addition of a thiol, via dehydroalanine formed from 
phenylselenocysteine.65 In this example, phenylselenocysteine has been incorporated into the 
genetic code using Schultz’s methodologies.  
 
One method involves the insertion of a phenylselenocysteine residue followed by subsequent 
chemical modification (Scheme 12). After introduction of the unnatural residue 19, selective 
elimination can yield the dehydroalanine residue 20. Michael addition of a nucleophilic thiol 
can then result in the incorporation of an unnatural amino acid. A disadvantage to this method 
of chemical modification is the possibility of poor stereocontrol upon Michael addition of the 
thiol.58,63 There have been several varied examples of unnatural thioether-containing amino 
acid side chains formed from a dehydroalanine intermediate. These modified side chains 
include alkene chains, amines, sugars, and phosphorus-containing species (Scheme 13). 
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Scheme 13 | Examples of thioether-containing amino acids introduced through the Michael 
addition of a thiol to dehydroalanine.55,63,65,66  
 
Alternatively, cysteine residues may be reacted with the dibromide 28 to produce a 
dehydroalanine residue (30) (Scheme 14).67 Again, the resulting dehydroalanine can then be 
attacked by a nucleophilic thiol in a Michael addition, generating an unnatural amino acid. 
Providing there is only one cysteine available to react, the formation of dehydroalanine can be 
chemoselective. 
 
Scheme 14 | Utilising the dibromide 28 to produce dehydroalanine.67 After the 
dehydroalanine residue 30 has been produced, subsequent reaction with a thiol can lead to 
the unnatural amino acid 31.  
 
 
 
 
 
19 
 
1.4 Directed evolution of NAL 
 
Sialic acids are a family of sugars characterised by a C-1 carboxylic acid and C-4 nitrogen 
substituent. N-Acetylneuraminic acid 49 is the most abundant sialic acid (Figure 3) and, as a 
result, N-acetylneuraminic acid is often referred to as sialic acid.68 Sialic acids can be found in 
many higher organisms, often as terminal residues of glycan chains, and are involved in many 
biological functions, such as cellular and molecular recognition.68 A key example of this is the 
involvement of sialic acids in the recognition of the influenza virus by cells.69 
 
 
Figure 3 | N-Acetylneuraminic acid, the most common sialic acid.68 
 
E. coli N-acetylneuraminic acid lyase (NAL) is a class I aldolase that catalyses the reversible 
condensation of pyruvate with N-acetylmannosamine (ManNAc), yielding N-acetylneuraminic 
acid (Neu5Ac) (Section 1.1.3).14,16  NAL has a high degree of substrate specificity with each of 
the four alcohols of ManNAc involved in key hydrogen bonding interactions with the enzyme. 
As a result of the very specific hydrogen bonding between ManNAc and NAL, the enzyme is 
only capable of accepting a narrow range of five and six carbon ManNAc derivatives. NAL is 
unable to catalyse the condensation of other more varied substrates efficiently.16,70  
 
1.4.1 Broadening the substrate specificity of NAL 
   
The carboxamide 32 (Figure 4) has been shown to inhibit influenza sialidases.16,71 Wild-type 
NAL is a poor catalyst of the aldol reaction for analogues of N-acetylneuraminic acid with the 
general structure 33, which are possible precursors of the carboxamide 32. Gavin Williams 
(University of Leeds) exploited directed evolution to broaden the substrate specificity of E. coli 
NAL in an attempt to allow the enzyme to accept molecules with the general structure 33 as 
substrates.72 
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Figure 4 | An inhibitor of influenza A sialidase 32 and N-acetylneuraminic acid analogues 
33.14,72-75 Wild type NAL is a poor catalyst for the synthesis of molecules such as 33, a possible 
precursor in the synthesis of 32.72 
 
With the knowledge of the active site in mind, broadening of the substrate specificity of N-
acetylneuraminic acid lyase involved saturation mutagenesis of the Glu192, Asp191 and 
Ser208 residues.76 After screening the resulting library of NAL variants, those altered at 
position 192 were found to accept several compounds of the general structure 33 as 
substrates more readily than wild-type E. coli NAL. This study led to the discovery of variant 
E192N, capable of accepting substrates of the general structure 33.14 The variant E192N was 
particularly efficient at catalysing the aldol reaction of the N-acetylneuraminic acid analogue 
(5R,6R)-7-(Dipropylamino)-4,5,6-trihydroxy-2,7-dioxoheptanoic acid (DPAH), which is a 
compound with general structure 33. E192N was capable of performing the retroaldol reaction 
on DPAH ~50 times more efficiently than wild type E.coli NAL (Scheme 15). The structure of an 
analogue of DHOB, the precursor to DPAH, in complex with the variant E192N has been 
determined crystallographically.16 The structural basis of the ability of the mutant to promote 
the reaction has been determined through crystal structure analysis of the E. coli NAL variant 
E192N in complex with a DHOB analogue. The crystal structure suggests that the propyl chains 
of the DHOB analogue orientate themselves into a hydrophobic pocket of the active site (see 
section 3.3 for more detail).16 These interactions enable the recognition of the unnatural 
substrates and subsequent catalysis of the reversible aldol condensation.  
21 
 
 
Scheme 15 | Directed evolution of NAL resulting in the discovery of the E192N variant. 71 This 
variant is capable of accepting and performing the reversible aldol reaction with a broad range 
of amide analogues of N-acetylneuraminic acid. The compounds ManNAc, N-acetylneuraminic 
acid and DPAH have been drawn in the open chain forms for clarity. 
 
1.4.2 Engineering of the stereocontrol of an NAL variant  
 
Though the E192N variant of NAL demonstrated broadened substrate specificity, poor 
stereocontrol was observed in the formation of the product (Scheme 16) limiting its utility in 
organic synthesis. Directed evolution was further utilised with NAL to engineer NAL variants 
that would act as complementary catalysts for the synthesis of two diastereomeric products. 
Using the E192N variant of NAL as a starting point, two further variants of NAL were developed 
for the synthesis of the two diastereomeric products.77  
 
Scheme 16| E192N exerts poor stereocontrol in the formation of the substrate DPAH. 
The two variants of NAL produced through the directed evolution of E192N NAL were 
(E192N/T167G) and (E192N/T167V/S208V). These variants provided complementary pairs 
which had favourable selectivity of roughly 40-fold for each of the diastereomers (Scheme 
17).77 
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Scheme 17 | Complementary 4S- and 4R- selective enzyme variants of E. coli NAL. These 
variants are capable of performing the aldol condensation stereoselectively with > 40:1 
diastereoselectivity.77  
 
1.4.3 Development of a method for the incorporation of unnatural amino acids into the 
active site of SaNAL 
 
Wild type S. aureus NAL contained no natural cysteine residues, so selective incorporation of 
unnatural amino acids could be achieved by first incorporating a cysteine through site-directed 
mutagenesis (step 1, Scheme 18). Recently, chemical modification of a cysteine residue has 
resulted in the incorporation of a thia-lysine analogue at the residue 165.78 Initially a cysteine 
residue was incorporated into residue 165 of SaNAL. This variant was then treated with the 
dibromide 28 to form the dehydroalanine residue dha (step 2, Scheme 18). Subsequent 
Michael addition of a thiol, cysteamine, resulted in the formation of the K165-γ-thialysine 
variant of SaNAL (step 3, Scheme 18). 
 
Scheme 18 | Modification of Lys165 SaNAL to K165- γ-thialysine. Either epimer of K165-γ-
thialysine may have formed. However, the crystal structure of the variant K165-γ-thialysine 
reveals only the amino acid with L-configuration.78 
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During the development of this methodology it was found that unfolding of the protein 
(facilitated by 6M urea) was necessary for the successful chemical modification of the active 
site residues. After chemical modification is complete the 6M urea is removed, allowing for the 
protein to refold (Scheme 19). The crystal structure of the SaNAL variant K165-γ-thialysine 
shows only the L-stereoisomer of the thialysine 165 residue (Figure 5). As both epimers of 
K165-γ-thialysine could result from the Michael addition of cysteamine, it is hypothesised that 
the R-stereoisomer was unable to refold after chemical modification. This may be a result of 
steric clash caused by the unnatural geometry of the incorporated side chain. 
 
Scheme 19 | Schematic of the chemical modification process of K165C. This shows the 
necessity of unfolding the protein in order to access active site residues for chemical 
modification. Protein is represented in green. 
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Figure 5 | Comparison of the catalytic residue 165 of wild type SaNAL (blue) to the 
chemically modified variant, K165-γ-thialysine (green). Both crystal structures have pyruvate 
bound to residue 165. The two residues show a high degree of overlap, despite the thioether 
bond in the chemically modified variant K165-γ-thialysine. Only the L-stereochemistry was 
observed in the crystal structure of K165-γ-thialysine. This figure was generated using PyMOL 
(PDB file 4AH7).78  
To gauge the efficiency of the modified protein, kinetic parameters were determined for the 
variant K165-γ-thialysine and the substrate N-acetylneuraminic acid. The unnatural protein 
was still found to catalyse the reverse aldol reaction of N-acetylneuraminic acid, though the 
efficiency of the protein had reduced to roughly 30% of the wild type SaNAL protein.78 It was 
also found that the optimal pH for the chemically modified protein (pH 6.8) was lower than the 
wild type SaNAL (pH 7.4).78 This shift in optimum pH was a direct result of the introduction of 
the thio-ether functionality. 
The preparation of this chemically modified protein required the establishment of a robust 
method for the chemical modification of active site SaNAL residues. This method could be 
exploited to incorporate a wide range of chemically modified proteins into the active site of 
SaNAL, which may lead to the broadening of the range of substrates accepted by SaNAL. 
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1.4.4 Development of a high throughput screen to identify chemically modified NALs with 
novel activity  
 
The activity of chemically modified SaNAL variants is currently being investigated within the 
Berry and Nelson groups. This research has involved screening the activity of chemically 
modified variants of SaNAL with readily available substrates. Several residues within the active 
site of SaNAL have been selected and replaced with cysteine through site-directed 
mutagenesis. These variants have been chemically modified by treatment with the dibromide 
28 and reacted with a range of readily-available thiols. Once the chemical modifications were 
complete, the chemically modified variants of SaNAL were screened with a range of readily 
available substrates in which an end point assay (thiobarbituric acid assay) was used to detect 
product formation.79,80 This is a relatively fast method to screen for novel activity and has been 
used to find the SaNAL variant F190-DHPC (see section 3.1.4). This approach, however, is 
limited to carbohydrates with α-hydroxy or α-NHAc aldehydes.  
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1.5 Conclusion and aim of the project 
 
Enzymes are incredibly efficient catalysts capable of dramatically catalysing reactions involving 
a small range of substrates. The reactivity of enzymes can be broadened further (beyond the 
canonical 20 amino acids) by the utilisation of cofactors. Taking inspiration from this, biologists 
and chemists have developed methods of tailoring the reactivity of proteins, enabling the 
catalysis of reactions that would not be possible with natural substrates.  
The aim of this project was to use chemical modification of specific residues within the active 
site of SaNAL to expand substrate specificity of the enzyme. Preparation of chemically 
modified variants will be performed as per section 2.2. This method is appropriate as it exploits 
the lack of cysteine residues within wild-type SaNAL and has previously been employed in the 
chemical modification of the active site residue K165 (section 1.4.3). The catalytic properties of 
these chemically modified variant enzymes will be investigated with analogues of N-
acetylneuraminic acid (see section 2.1 for substrate design and synthesis). 
Major considerations for the project will include the selection of active site SaNAL residues to 
target for the chemical modification . Thiols that will be used for the chemical modification of 
these residues must be considered and selected, and potential substrates will be designed for 
testing with the chemically modified SaNAL variants in kinetic parameter assays.  
This project may yield insight into how chemical modification of SaNAL could expand the 
catalytic repertoire of the enzyme. 
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Results and Discussion: Substrate and 
protein preparation 
2.1 General overview of substrate synthesis 
 
This Chapter describes the synthetic routes to the four potential substrates (4R,5R,6R)-5-
acetamido-4,6,7-trihydroxy-2-oxoheptanoic acid (ATOA), (5R,6R)-7-(dipropylamino)-4,5,6-
trihydroxy-2,7-dioxoheptanoic acid (DPAH), the enantiomer of N-acetylneuraminic acid (ent-
NANA) and the enantiomer of  (4R,5R,6R)-5-acetamido-4,6,7-trihydroxy-2-oxoheptanoic acid 
(ent-ATOA) (Figure 6). All of these compounds contain a common substructure, which is shown 
in red in Figure 6. Despite the common substructure, it was decided to develop three 
alternative synthetic approaches, due to the diverse stereochemistry and functionality of the 
compounds. These compounds were chosen as they are analogues of N-acetylneuraminic acid, 
so contain a 1,3 alcohol ketone relationship which is necessary for an aldol reaction. The 
potential substrates (Figure 6) were synthesised in order to explore the reactivity of chemically 
modified SaNAL variants by varying length of substrate, stereochemistry and functionality. 
More detailed reasoning for the selection of each substrate is discussed in sections 3.1.1 
(ATOA), 3.1.6 (ent-ATOA), 3.2.4 (ent-NANA) and 3.3 (DPAH). 
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Figure 6 | Four potential substrates for NAL and NAL variants. The common substructure 
found in each compound is highlighted in red, note the configuration within the common 
substructure vary. For clarity the potential substrates are shown in the open chain forms. 
 
28 
 
Scheme 20 outlines the three alternative synthetic approaches to the potential substrates. 
Approach A would involve the truncation of the full length natural substrate, N-
acetylneuraminic acid, to give the potential substrate ATOA. A beneficial aspect of this 
synthetic approach is that all three stereocentres of ATOA are already defined within the 
starting material, therefore removing the potentially problematic issue of stereocontrol. 
 
 
 
Scheme 20 | Three alternative approaches to the potential substrates. Approach A would 
involve the truncation of N-acetylneuraminic acid.82 Approach B would utilise a 
chemoenzymatic strategy.71 Approach C would involve a more direct chemical synthetic 
strategy.81 The compounds ATOA, N-acetylneuraminic acid, DPAH, and ent-ATOA  have been 
drawn in the open chain forms. 
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Approach B is a chemoenzymatic approach and would exploit an enzyme variant previously 
tailored by directed evolution to enable the synthesis of DPAH (Scheme 20). Initially the 
aldehyde 34 would be prepared from ribonolactone 35 and would contain most of the 
functionality of DPAH. The E192N variant of E. coli NAL (section 1.4.1) could then be utilised in 
conjunction with pyruvate to convert aldehyde 34 into the final product DPAH.  
 
Finally, Approach C would exploit a more direct chemical synthetic strategy and would be 
employed for the synthesis of both ent-NANA and ent-ATOA. This approach would be based 
on three key steps. Initially a Petasis reaction would be performed involving an aldehyde (e.g. 
39), an amine 40 and a boronic ester 41 to give an alkene 37. The boronic ester 41 would then 
be reacted with a nitrone 38 in a 1,3-dipolar cycloaddition to produce the compound 36, a 
process which would result in the formation of two new stereocentres. Once compound 36 
was synthesised, an elimination step would lead to the compound ent-ATOA (Scheme 20). An 
analogous approach could be used for ent-NANA. The success of this synthetic strategy would 
rely on the precedented high degree of stereocontrol.81 
 
2.1.1 Synthesis of the truncated N-acetylneuraminic acid analogue, ATOA  
 
Initially N-acetylneuraminic acid was treated with Dowex 50W H+ ion exchange resin in 
methanol at 70 °C; after crystallisation, the protected sugar 42 was obtained in 50% yield. 500 
MHz 1H NMR spectroscopic analysis confirmed that only one anomer of compound 42 had 
been formed (Scheme 21). The compound 42 was treated with 2.5 equivalents of periodic acid 
in water, resulting in the formation of the hydrated aldehyde 43 which was purified by basic 
ion exchange column chromatography. 
30 
 
 
Scheme 21 | Synthesis of truncated N-acetylneuraminic acid analogue ATOA. The 
intermediates in parenthesis were not purified and characterised. Route adapted from patent 
82. 
 
Initial attempts at the reduction of the hydrated aldehyde 43 using 2.5 equivalents of sodium 
borohydride in methanol at 0 °C led to the over-reduced sugar 48 (Scheme 22). The over-
reduction could be circumvented by the conversion of the methyl ester 43 into the less 
reactive carboxylic acid salt 44. Thus the methyl ester 43 was suspended in 0.6 M aqueous 
sodium hydroxide until complete formation of the salt 44 was observed by LCMS. The 
carboxylate 44 was then treated with 2.5 equivalents of sodium borohydride to give 
compound 45 (which was observed by LCMS). For the purpose of purification, compound 45 
was resuspended in methanol containing Dowex 50W H+ resin resulting in the formation of 
sugar 46 which was isolated via ion exchange chromatography. This four step process from 
protected N-acetylneuraminic acid 42 consistently gave the truncated sugar 46 in >95 % yield. 
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Scheme 22 | Over reduction of the sugar 43 to the sugar 48. Reduction with NaBH4 in 
methanol at 0 °C led to over reduction of sugar 43. 
 
The truncated sugar 46 was treated with aqueous sodium hydroxide to give the intermediate 
47 (observed by LCMS). After neutralisation with Dowex 50W H+ ion exchange resin and 
concentration, the carboxylic acid intermediate 47 was treated with aqueous formic acid at 80 
°C to provide ATOA in 50% yield over two steps after reverse phase column chromatography. 
The overall yield of the synthesis of ATOA was 25% from N-acetylneuraminic acid.  
 
2.1.2 Synthesis of the substrate DPAH 
 
The substrate DPAH was prepared by the chemoenzymatic approach B (Section 2.1, Scheme 
20). The synthesis began with the treatment of the ribonolactone 35 with acetone and conc. 
H2SO4 to give the acetonide 49 in 70% yield (Scheme 23). Treatment of the alcohol 49 with 
iodine, triphenylphosphine and imidazole led to the formation of the unstable iodolactone 50 
in 68% yield. The iodolactone 50 was treated with zinc/copper couple in refluxing 4:1 acetone–
water; the carboxylic acid 51, which was used without any purification, was obtained in 77% 
yield. The carboxylic acid 51 was treated with EDC, HOBt and dipropylamine to form the amide 
52 in 69% yield. The amide 52 was then subjected to 9:1 TFA–water to give the diol 53 in 92% 
yield. 
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Scheme 23 | Chemoenzymatic approach to the synthesis of the substrate DPAH.71 
 
The alkene 53 was treated with ozone at –78 °C until the ozonolysis was deemed to be 
complete (reaction mixture had turned blue), at which point dimethyl sulfide was added to 
reduce the intermediate ozonide.  The intermediate aldehyde 34 was concentrated in vacuo 
and used without any further purification. The final steps in the synthesis of DPAH involved the 
resuspension of the intermediate aldehyde 34 in 50 mM Tris HCl buffer at pH 7.4; the 
intermediate aldehyde 34 was then treated with a five-fold excess of sodium pyruvate (in 50 
mM Tris HCl buffer at pH 7.4) and the enzyme  E192N (in 50 mM Tris HCl buffer at pH 7.4). 
After 24 hours the reaction was stopped by treatment with 2M aqueous formic acid and 2M 
aqueous ammonium hydroxide, followed by decomposition of the excess pyruvate via 
treatment with bakers’ yeast. DPAH was isolated from the aldolase-catalysed step in 60% yield 
after purification by ion exchange chromatography. The distereoselectivity of the aldolase-
catalysed step was consistent with that previously reported (~ 75:25).72,76,83 
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2.1.3 Synthesis of the enantiomers of N-acetylneuraminic acid and ATOA 
 
 
Scheme 24 | Synthetic route used for ent-ATOA. This synthesis involved a Petasis reaction, a 
1,3 dipolar cycloaddition and a deprotection reaction.81 
 
The synthesis of ent-ATOA (Scheme 24) began with the deprotection of the acetonide 54 by 
treatment with TFA in water, followed by immediate concentration of the reaction mixture to 
allow purification by reverse phase column chromatography to give a crude aldehyde 39 which 
was used without further purification (Scheme 24). The crude aldehyde 39 was treated with 
the vinyl boronic ester 41 and the amine 55 in 4:1 ethanol-water for 3 days at 50 °C to give the 
intermediate alkene 56 (which was detected by LCMS). TFA was then added to the reaction 
mixture and the solution was stirred at 50 °C until complete formation of the primary amine 
intermediate 57 was observed by LCMS; the solution was then reduced in vacuo and the 
primary amine 57 used without any further purification. The primary amine intermediate 57 
was resuspended in methanol containing 2 equivalents of sodium bicarbonate and treated 
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with 1.1 equivalents of acetic anhydride for 1 h at room temperature. The amide 58 was 
obtained in 35% yield after purification. 500 MHz 1H NMR spectroscopic analysis of the amide 
58 showed that only one stereoisomer had been obtained. The stereoselectivity of the 
reaction may be rationalised in terms of coordination of the boronic ester 60 to the α-hydroxyl 
group of the imine intermediate 59 (Scheme 25, Newman projections 61 and 62).  
 
Scheme 25 | Theoretical rationalisation of the stereochemical outcome of the petasis 
reaction of the aldehyde 39, depicting the coordination of boronic ester to the α-hydroxyl of 
the imine intermediate 61.  
 
The alkene 58 was treated with the nitrone 38 in dioxane at 30 °C for two weeks, after which 
isooxazolidine 36 was isolated in 30% yield as a single regio- and stereoisomer (judged by 500 
MHz 1H NMR spectroscopy). The stereochemical outcome can be rationalised through the 
minimisation of steric clash between the alkene substituent 58 and the nitrone 38 (transition 
state diagram in Scheme 26, transition state 63). 
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Scheme 26 | Proposed transition state for the 1,3-dipolar cyclisation of the alkene 58 and 
the nitrone 38. 
 
Compound 36 was then treated with sodium methoxide in methanol, followed by the addition 
of water, resulting in the elimination to give ent-ATOA , isolated in 60% yield after purification 
via ion exchange chromatography eluting with 0–2M formic acid.  
 
The synthesis of the compound ent-NANA was performed using the same strategy as the 
synthesis of the compound ent-ATOA, and can be seen in Scheme 27. The synthesis began 
with the compound 64 (L-arabinose) which, after Petasis reaction, deprotection and amide 
formation gave the alkene 65 in 50% yield; once again, only one stereoisomeric product was 
observed by 500MHz 1H NMR spectroscopy. Subsequently, the 1,3-dipolar cycloaddition 
between the alkene 65 and the oxazole 38 gave the isooxazolidine 66 in 55% yield. Treatment 
of the isooxazolidine 66 with sodium methoxide in methanol, and then water, led to the 
compound ent-NANA as a single diastereomer in 55% yield after ion exchange 
chromatography.  
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Scheme 27 | Route used for the synthesis of ent-NANA.81 
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2.2 Preparation and characterisation of enzymes  
 
This section describes the approach used to incorporate unnatural amino acids into the active 
site of SaNAL. To illustrate the approach, the chemical modification of the E192C variant 
(Scheme 28) is described in detail. Methods for the expression, purification, chemical 
modification and characterisation of the modified enzymes are described. The process began 
with the glycerol stock solutions of XL10-Gold cells, containing the gene encoding either the 
E192C or F190C variant, and led to the production of chemically modified proteins. An example 
of this overall process – leading to the variant E192-DHPC – is shown in Scheme 28. The 
positions E192 and F190 were both chosen as modifications at these positions have been 
shown to broaden the substrate specificity of NAL (see sections 1.4.1 and 3.1.4 for more 
details on the position E192 and F190 respectively). 
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Scheme 28 | An overview of the integrated biological and chemical approach used to modify 
SaNAL to yield a protein containing an unnatural amino acid. In this example the thiol, 
thioglycerol, was used to produce the E192-DHPC SaNAL variant. 
 
2.2.1 Expression and purification of the SaNAL variants E192C and F190C 
 
XL10-Gold cells containing the genes encoding either the E192C or F190C SaNAL were provided 
by Nicole Timms and Claire Windle (University of Leeds). The plasmid DNA from the XL10 gold 
cells was isolated (Section 4.1.10) and analysed by DNA gel electrophoresis (Figure 7 and 
Section 4.1.9). Sequencing of the isolated DNA confirmed that the correct gene sequences 
were present. The DNA was then retransformed into BL21-Gold (DE3) cells and stored at -80 °C 
ready for protein expression.  
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Figure 7 | An example agarose gel showing the plasmid pKK223-3 containing either the wild-
type SaNAL gene (lane 2), or the SaNAL E192C gene (lane 3). Promega 1kb DNA ladder is 
shown in lane 1. DNA was isolated from XL10-Gold cells.  
 
The E192C and F190C variants of SaNAL were expressed on a 1-6 L scale using the BL21-gold 
(DE3) cells (Section 4.1.7). The expressed proteins, which contain hexahistidine tags, were 
purified using nickel affinity purification (Section 4.1.15). SDS-PAGE analysis (Section 4.1.14) of 
E192C at different stages of purification can be seen in Figure 8, and a single band at ~34 kDa 
in lane 9 of the SDS-PAGE gel indicates isolated purified E192C protein.  
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Figure 8 | An example SDS-PAGE of the stages of the nickel affinity purification of SaNAL 
E192C protein. Lane 1) NEB prestained protein marker, broad range (7-175 kDa). 2) IPTG 
induced BL21-Gold (DE3) cells. 3) pellet after cell lysis. 4) supernatant after cell lysis. 5-8) Four 
tris buffer washes of the nickel resin after the His6-tagged SaNAL E192C protein had been 
bound. 9-10) Two elutions using 0.5 M imidazole in buffer, which facilitated the displacement 
of the SaNAL E192C protein from the nickel resin. A single band, at approximately 34 kDa, is 
visible in lane 9 which corresponds to pure protein.  
 
Following purification, protein samples were dialysed into 50 mM ammonium acetate buffer 
(Section 4.1.16), and the concentration measured (Section 4.1.17). The protein was aliquoted 
into 5-10 mg samples, which were then lyophilised. Lyophilised samples were characterised by 
mass spectrometry (Section 4.1.19). As an example, Figure 9 shows both the multiple mass-
charge state spectrum for E192C, as well as the deconvoluted spectrum of the same sample. 
The multiple mass-charge state spectrum of E192C is the primary data obtained and shows the 
multiple charge states of the protein, as proteins have many sites that can be protonated. 
These charge states are related to the mass of the protein through the m/z (mass-to-charge) 
ratio.84,84b The peak with a charge state of 31+ has been highlighted in the multiple charge-
state spectrum as an example (Figure 9). Deconvolution of the multiple mass-charge state 
spectrum was routinely performed by James Ault (University of Leeds) using software provided 
with the mass spectrometer equipment (Section 4.1.19).  
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The yield of E192C or F190C after purification was typically 50-70 mg per litre of expression 
culture. Lyophilised purified protein samples were stored at −20 °C until they were needed for 
chemical modification. 
 
 
Figure 9 | ESI-MS spectra of SaNAL E192C. (Top) showing mass charge states (Bottom) 
showing deconvoluted spectrum. Measured mass = 33970.559 Da. Calculated mass = 33969.00 
Da.  
 
2.2.2 Preparation of a chemically modified SaNAL variant  
 
The methodology used for the chemical modification of SaNAL had already been established 
within the Berry group and had been successfully used to modify cysteine variant SaNAL 
proteins. The chemical modification of either E192C or F190C began with the resuspension of 
the lyophilised protein (2 mg/mL) in 50 mM sodium phosphate buffer pH 8.0 containing 6 M 
urea. Urea-facilitated unfolding of the protein was necessary to allow accessibility of the active 
site cysteines to the chemical reagents. To a solution of unfolded protein, the dibromide 
compound 28 in DMF (12.8 mg in 97 µL per 2mg of protein) was added and the solution was 
31+ 
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incubated for 1.5 h at 37 °C. At this point, a 70 µL sample of the reaction mixture could be 
buffer exchanged into 50 mM ammonium acetate (Section 4.1.19) and used for mass 
spectrometric analysis to allow for the observation of the completion of the reaction. The 
conversion was deemed to be complete when all the cysteine in the protein has been 
converted to dha. An observed decrease in mass of 34 Da would be consistent with the 
conversion of cysteine containing protein to dha containing protein.  
 
Upon complete conversion of either E192C to E192dha, or F190C to F190dha, the protein was 
reacted with a thiol reagent. In this example, thioglycerol in 1.5 M Tris/HCl pH 8.8 (36 mg in 
114 µL per 2 mg of protein), was added and the buffered solution containing E192dha was re-
incubated for 2 h at 37 °C. At this point 70 µL of the protein reaction mixture could again be 
buffer exchanged (into 50 mM ammonium acetate) and used for mass spectrometric analysis. 
The resulting modified SaNAL protein variant was then dialysed into sodium phosphate pH 8.0 
buffer containing 6M urea, followed by dialysis into sodium phosphate buffer pH 8.0 and then 
two rounds of dialysis into 50 mM Tris HCl buffer pH 7.4 (section 4.1.23).  Nicole Timms 
(University of Leeds) had previously demonstrated, using circular dichroism, that this 
procedure resulted in refolding of related chemically modified proteins at positions 165 of 
SaNAL.84b 
 
Finally the modified protein was concentrated to 5 mL (section 4.1.18) and purified by size 
exclusion chromatography (Section 4.1.24), a process in which the unfolded protein could be 
separated from the refolded modified protein (Figure 10). The protein collected after size 
exclusion chromatography was then concentrated (Section 4.1.18), and assessed using mass 
spectrometry (Figure 11).  
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Figure 10 | Size exclusion column trace of the purified SaNAL E192-DHPC protein. The first 
peak represents unfolded protein and the second peak represents the refolded modified 
protein.  The red markings show where fractions (2 mL per fraction) were collected. 
 
  
Figure 11 | ESI-MS spectra of SaNAL E192-DHPC (Top) showing mass charge state (Bottom) 
showing deconvoluted spectrum. Measured mass = 34041.00 Da. Calculated mass = 34043.42. 
 
31+ 
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2.2.3 Scope of the chemical modification of SaNAL 
 
Twelve successful large scale (20-40 mg) modifications were performed at position E192C, and 
an additional four modifications were performed at the position F190C (see appendix I). Figure 
12 shows the successful modifications performed at position E192C. The modifications cover a 
range of functional groups and include straight chain, branched and cyclic species.  
 
Four modifications resulted in unnatural amino acids with carbonyl based functionality, E192-
CMC (an analogue of glutamic acid), E192-MCMC, E192-ACEC and E192-AMCEC. Interestingly, 
E192-ACEC and E192-AMCEC made use of cysteine as the nucleophile. There were several 
modifications which resulted in amino acids with alcohol based functionality, such as E192-
DHPC, E192-HPC (an analogue of threonine) and E192-HBC. The use of aminoethanethiol as 
the nucleophile resulted in the lysine analogue E192-AEC. Several of the modifications were 
hydrocarbon-based, resulting in non-polar unnatural side chains such as E192-PC, E192-CPC 
and E192-CHC. Finally E192-HEBC combines both a greasy hydrocarbon chain and a terminal 
alcohol side chain.  
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Figure 12 | Overview of the successful chemical modifications of SaNAL at position E192C. 
Each structure represents the unnatural side chain incorporated through chemical 
modification into the position E192. 
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Not all of the modifications attempted at position E192C were successful. Attempting to 
modify E192C with compounds which had a thiol directly attached to an aromatic ring such the 
thiols 68 and 69 (Figure 13) did not result in any detectable product upon mass spectrometric 
analysis of the reaction mixture. The thiol 67 (Figure 13) represents an example of a 
modification which successfully incorporated into position E192C (detected by mass 
spectrometric analysis of the reaction mixture) though the protein continuously precipitated 
out of solution upon dialysis of the reaction mixture.  
 
Figure 13 | The thiols used in failed modifications attempts using the modified SaNAL 
protein E192C.  
 
The four modifications performed at position F190C can be seen in Figure 14. The majority of 
these modifications contained alcohol-based functionality, F190-DHPC, F190-HBC and F190-
HPC. F190-PC provides a hydrocarbon based functional group.  
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Figure 14 | Thiols used to chemically modify position F190C of SaNAL. 
 
2.3 Conclusion  
 
The four potential substrates ATOA, DPAH, ent-NANA and ent-ATOA were synthesised 
through three different approaches (Section 2.1). Together with the chemically modified 
proteins, the effect of chemical modification of SaNAL on substrate acceptance could then be 
measured via kinetic screening. 
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Results and Discussion: Kinetic 
Characterisation 
 
Kinetic parameters of all SaNAL variants with any of the N-acetylneuraminic acid analogues 
were determined using an established coupled enzyme assay (Scheme 29 and Section 
4.1.21).72,85 This assay measures the initial rate of the reverse aldol reaction through a change 
in absorbance at 340 nm. The change in absorbance is a result of the consumption of NADH, a 
co-factor of L-lactate dehydrogenase utilised in the reduction of pyruvate (a product of the 
retro aldol reaction). Assuming steady-state kinetics, the rate of consumption of NADH is equal 
to the rate of turnover of substrate by the aldolase.  
 
 
Scheme 29 | Representation of the coupled enzyme assay to determine the kinetic 
parameters of all SaNAL variants. The cleavage of the full length substrate (in this case N-
acetylneuraminic acid) is catalysed by an NAL enzyme resulting in pyruvate and an aldehyde. 
The reduction of pyruvate, catalysed by L-lactate dehydrogenase, results in a decrease in the 
concentration of NADH, which absorbs at 340 nm. 72,85 For clarity the carbohydrates Neu5Ac 
and ManNAc are shown in the open chain forms. 
Each measurement was performed in a Tris/ HCl pH 7.4 buffer at 37 °C and the change in 
absorbance recorded over a period of 1 minute. Each assay consisted of 0.5 units of lactate 
dehydrogenase, 0.2 mM of NADH, between 0.03 and 0.1 mg/mL of SaNAL variant, and a varied 
concentration of N-acetylneuraminic acid or N-acetylneuraminic acid analogue.  
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 To obtain the kinetic parameters kcat, KM and kcat/KM for an aldolase variant, several 
measurements were performed using a fixed concentration of aldolase and a varied 
concentration of substrate. The specific activity for each concentration of substrate could be 
calculated from the change in absorbance measured, and a plot of the specific activity versus 
concentration of substrate could then be used to calculate kinetic parameters for the enzymes 
i.e. the kcat, KM and kcat/KM values.  
Before the catalytic parameters of the unnatural amino acid-containing SaNAL variants were 
determined, kinetic parameters for the enzymes SaNAL and the SaNAL variant E192N with the 
substrates N-acetylneuraminic acid and the N-acetylneuraminic acid analogue DPAH were 
determined. The kinetic parameters measured for these aldolase enzymes would provide 
benchmarks to which other SaNAL variants could be compared. Determining the kinetic 
parameters for the enzyme SaNAL with the substrate N-acetylneuraminic acid was an obvious 
choice as SaNAL is the wild type enzyme and N-acetylneuraminic acid is the natural substrate. 
The SaNAL mutant E192N with the N-acetylneuraminic acid variant DPAH as the substrate was 
chosen, as the E. coli NAL variant E192N had previously been engineered to accept this 
substrate.16 The kinetics of the SaNAL variant of E192N with the N-acetylneuraminic acid 
analogue DPAH had not been previously evaluated.  
Kinetic parameters for each of the four enzyme/substrate combinations were established by 
first measuring the change in absorbance using a fixed amount of protein and an increasing 
concentration of substrate (up to 15 mM). The specific activity for each concentration of 
substrate was then calculated from these values. Graphs of specific activity against substrate 
concentration were plotted in order to establish the Michaelis-Menten kinetic parameters 
(Figure 15). 
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Figure 15 | Activity plots of four SaNAL variants with N-acetylneuraminic acid and DPAH as 
substrates. A) Wild-type SaNAL with N-acetylneuraminic acid; B) Wild-type SaNAL with the N-
acetylneuraminic acid analogue DPAH; C) The SaNAL variant E192N with N-acetylneuraminic 
acid; D) The SaNAL variant E192N with the N-acetylneuraminic acid analogue DPAH. 
 
Table 1 shows the kinetic parameters (kcat, KM and kcat/KM) for all four of the SaNAL aldolase/ 
substrate combinations examined, as well as those for the E. coli NAL combinations for 
comparison. The kcat, KM and kcat/KM values for SaNAL with the substrate N-acetylneuraminic 
acid are comparable to others obtained within the Berry lab. As previously observed with N-
acetylneuraminic acid 78, the kcat is lower for S. aureus NAL compared to that of E. coli NAL. The 
KM for SaNAL is also lower than that of E. coli NAL. This has resulted in a kcat/KM of 52.1 min-1 
mM-1, similar to the kcat/KM of E. coli NAL, with N-acetylneuraminic acid as the substrate. 
Similarly, SaNAL with DPAH (as a substrate) suffers a decrease in kcat as well as a decrease in 
KM, when compared to kcat and KM of E. coli NAL with DPAH. This, again, results in a small 
overall decrease in specific activity (kcat/KM).  
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Table 1 | The kinetic parameters observed for SaNAL variants with either N-
acetylneuraminic acid or DPAH as a substrate. Also included are published results for the E. 
coli NAL variants with N-acetylneuraminic acid and DPAH for comparison.16 As previously 
stated (Section 1.4.3), S. aureus NAL was used throughout this investigation as it contains no 
natural cysteines. 
 
 
E. coli 
NAL 16 
S. aureus 
NAL 
E. coli 
E192N 16 
S. aureus 
E192N 
N-acetyl 
neuraminic 
acid 
kcat / min-1 260 + 6 166.7 + 9.8 170 + 10 96.5 + 20.1 
KM / mM 4.4 + 0.3 3.2 + 0.5 38 + 5 8.7 + 3.8 
kcat/KM / min-1 mM-1 59 52.1 4.4 11.1 
DPAH 
kcat / min-1 73 + 4 24.8 + 1.1 130 + 3 56.5 + 2.4 
KM / mM 11 + 2 5.17 + 0.6 0.4 + 0.04 1.7 + 0.2 
kcat/KM / min-1 mM-1 7 4.8 340 33.2 
 
Kinetic parameters with the SaNAL variant E192N and the N-acetylneuraminic acid analogue 
DPAH had not previously been performed. Table 1 shows a comparison between the kinetic 
parameters observed with SaNAL E192N and the published results for E. coli NAL E192N with 
DPAH. The difference in kcat between the two proteins follows the same trend as E. coli NAL 
and SaNAL, exhibiting a decrease in rate constant. There is, however, a ~4-fold increase in KM 
from 0.4 mM with E. coli NAL E192N to 1.7 mM in SaNAL E192N. This increase in KM results in a 
~10-fold decrease in kcat/KM for SaNAL E192N when compared to E. coli NAL E192N with DPAH.  
The greatly increased KM value for the SaNAL E192N variant in comparison to the E. coli NAL 
E192N variant can be rationalised by comparing the crystal structures of the two proteins 
(Figure 16). It has previously been established that the two propyl side chains of the N-
acetylneuraminic acid analogue DPAH sit within a hydrophobic pocket of the active site of the 
E192N variant of E. coli NAL.16 
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Figure 16 | Representation of the differences in the active sites of the E. coli NAL variant 
E192N and the wild-type SaNAL active site. Top) Sequence alignment of E. coli NAL E192N and 
wild-type SaNAL from residues 165 to 252. The highlighted residues were shown to be 
important to the recognition of the substrate DPAH,16 residues highlighted in yellow are 
identical between proteins, and residues highlighted in green differ between proteins. 
Bottom) Structural alignment of the crystal structures of E. coli NAL E192N (light orange) in 
complex with pyruvate and the DPAH analogue THB (purple), and SaNAL (cyan) in complex 
with pyruvate. This Figure was generated using PyMOL (PDB file 4AH7 and 2WPB).16,78  
 
When overlaying the crystal structure of the E. coli NAL variant E192N (in complex with a 
DPAH analogue) with the crystal structure for SaNAL, it becomes clear that several of the 
residues which make up the hydrophobic pocket are different. The residues 247, 251 and 252 
are particularly interesting because in the wild-type SaNAL structure the residues appear to 
reduce the size of the pocket in which the two propyl chains of DPAH would rest. A smaller 
hydrophobic pocket in the active site, and therefore possibly less efficient DPAH binding, may 
be the reason for the increased KM value observed with SaNAL E192N when compared to the E. 
coli NAL variant. 
 
Despite the reduction in efficiency between the SaNAL E192N variant when compared to the E. 
coli variant, the E192N variant of SaNAL still exhibits a ~6 fold improvement in kcat/KM when 
compared to the wild type SaNAL and the substrate DPAH. The study of the kinetic parameters 
of SaNAL and the variant E192N provide two benchmarks in activity with which to compare the 
chemically modified variants of SaNAL.  
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3.1 Kinetic characterisation of chemically modified SaNAL variants using 
truncated N-acetylneuraminic acid analogues as potential substrates  
 
Both site-directed and saturation mutagenesis of the active site of N-acetylneuraminic acid 
lyase has led to an increased level of understanding of the mechanism of catalysis.15 For 
instance, mutagenesis and quantum mechanical molecular modelling (QM/MM) studies have 
shown that the residue Y137 is integral to the catalytic activity of the enzyme, acting as a 
proton donor in the forward aldol reaction (Figure 17).15,86 The variant Y137F resulted in a 
dramatic reduction in activity with N-acetylneuraminic acid as a substrate compared to the 
wild-type protein. Furthermore, the variant Y137A has shown no detectable activity with N-
acetylneuraminic acid as a substrate.15 More interestingly, studies of modifications of position 
E192 have resulted in the discovery of the N-acetylneuraminic acid lyase variant E192N which 
demonstrated switched substrate specificity and allowed the protein to carry out the retro-
aldol reaction with the unnatural substrate DPAH (kcat/KM = 336 min-1mM-1) more efficiently 
than cleavage of N-acetylneuraminic acid by wild type E.coli NAL (kcat/KM = 59 min-1 mM-1).72 
 
The positions targeted in this project needed to be relevant to the recognition of the substrate 
but not integral to the catalytic mechanism. It was therefore envisaged that chemical 
modification at position 192 might improve the catalysis of the cleavage of a range of N-
acetylneuraminic acid analogues.  
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Figure 17 | Schematic of the active site of E. coli NAL with ManNAc and pyruvate bound 
showing H bonding between ManNAc and Glu192, Asp191 and Ser208. The donation of a 
proton from Y137 occurs during the formation of N-acetylneuraminic acid. Adapted from 72,87. 
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3.1.1 Previous modifications of position E192 of E. coli NAL with the aim of catalysing the 
retroaldol reactions of truncated N-acetylneuraminic acid analogues  
 
Research performed by Amanda Bolt (University of Leeds) aimed to produce an aldolase 
capable of performing the retro-aldol reaction with the truncated N-acetylneuraminic acid 
derivatives 70 and 71 (Figure 18). The compounds 70 and 71 are structurally related to N-
acetylneuraminic acid and ATOA, and the common functionality is highlighted in red in Figure 
18. Each of the four compounds had the same sterochemical configuration at C-4, C-5 and C-6. 
The compounds 70 and ATOA differ only in the substitution at position C-5.  
 
 
Figure 18 | The truncated sialic acid analogues 70 and 71 used by Amanda Bolt (University of 
Leeds), and both N-acetylneuraminic acid and the truncated analogue ATOA. Features 
common to all compounds are highlighted in red.  
 
A saturation mutagenesis library at residue 192 (E192X) was created and then tested for 
catalytic activity using a single concentration of each of the N-acetylneuraminic acid analogues 
70 and 71. Each assay used 0.1 mM of substrate and an E192X variant.87 The results from the 
E192X library with potential substrates 70 and 71 can be seen in Figure 19 and show an almost 
complete lack of activity. It was concluded that no E192X variant was capable of catalysing the 
aldol reaction of the truncated N-acetylneuraminic acid analogues 70 and 71. 
 
 
 
ATOA 
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Figure 19 | Catalysis of E192X variants observed with 0.1 mM of substrate and 0.1 mg/mL of 
enzyme. Left) The rate of change in absorbance observed with compound 70. Right) The rate 
of change in absorbance observed with compound 71. The results shown have been 
background corrected, whereby measurements conducted in the absence of substrate were 
deducted from the measurements with substrate. Figure adapted from 87. 
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3.1.2 Chemical modification at position 192 of SaNAL with the aim of catalysing the retro-
aldol reaction of the truncated sialic acid analogue ATOA 
 
One rationale for the lack of activity found with the truncated N-acetylneuraminic acid 
analogues 70 and 71 with the variant E192X library (Section 3.1.1, Figure 19) may be that the 
side chains at position 192 are too distant from the truncated analogues 70 and 71 to allow 
effective recognition of the substrate (Figure 20).   
 
 
Figure 20 | Representation of a truncated N-acetylneuraminic acid analogue in the active site 
of NAL. The residue at position 192 may be too far from the truncated N-acetylneuraminic acid 
analogue to allow recognition of the truncated substrates 70 and 71. The representation in the 
figure assumes that truncated substrates may maintain interactions with Ser208 and Asp191 
observed with N-acetylneuraminic acid, while no interaction with 192 may be possible. 
 
An investigation into whether the chemical modification of SaNAL variants could enable 
catalysis of the retro-aldol reaction of truncated N-acetylneuraminic acid analogues had not 
previously been performed. The aim was to examine the kinetic parameters of the SaNAL 
variants chemically modified at position 192 in the reaction with the truncated N-
acetylneuraminic acid analogue ATOA. The side chains of the chemically modified E192 
variants may provide unnatural functionality to the enzyme, and possibly promote activity with 
the truncated N-acetylneuraminic acid analogue ATOA. An example of how unnatural amino 
acids might increase the catalysis of the cleavage of truncated N-acetylneuraminic acid 
analogues can be seen in Figure 21. It is possible that the absence of interactions between the 
alcohols of the truncated N-acetylneuraminic acid analogue ATOA and the E192 residue could 
be responsible for the lack of catalysis (Figure 21 B). If residue 192 was to be lengthened 
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through chemical modification (e.g. to give the chemically modified SaNAL variant E192-CMC), 
an interaction between the truncated N-acetylneuraminic acid analogue ATOA and the side 
chain might be restored (Figure 21 C). Figure 21 is however speculative and a thorough 
investigation into the effects of all the chemical modification of side chains at position E192 
was needed. 
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Figure 21 | A graphical representation of the active site of NAL in complex with truncated N-
acetylneuraminic acid analogue ATOA and an unnatural amino acid at position E192. A) The 
hydrogen bonding between N-acetylneuraminic acid and E192 of wild-type SaNAL. B) The 
truncated substrate ATOA may not be able to make such hydrogen bonding interactions. C) 
Incorporation of an unnatural lengthened glutamic acid analogue into position E192 may allow 
hydrogen bonding between the truncated substrate and the modified enzyme.  
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3.1.3 Evaluation of the catalytic ability of SaNAL variants, chemically modified at position 
192, with the truncated N-acetylneuraminic acid analogue ATOA as a substrate 
 
Single concentration kinetic measurements were performed with all of the variants of SaNAL 
that had been chemically modified at position 192. Each measurement was performed using a 
high (10 mM) concentration of the truncated N-acetylneuraminic acid analogue ATOA and 0.1 
mg/mL of enzyme. The results of these experiments can be seen in Figure 22, as well as the 
background uncorrected measurements and the background measurements. 
 
 
Figure 22 | The single point kinetic measurements performed using the truncated N-
acetylneuraminic acid analogue ATOA. A) The uncorrected change in absorbance observed 
over the period of 1 minute. Each measurement was performed using 10 mM of substrate and 
0.1 mg/mL of protein. B)  The unnatural amino acid side chains of chemically modified proteins 
used in the assay. C) The background change in absorbance observed over 1 min. These 
measurements are the sum of two control experiments: (i) with 10 mM of substrate and no 
aldolase, and (ii) with 0.1 mg/mL of aldolase and no substrate.  D) The background corrected 
change in absorbance observed over one minute. 
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The activities even at the high concentration of the compound ATOA proved modest and in 
some cases the background activity is almost as high as the uncorrected measurement (i.e. 
E192N).  Although modest, there was significant increase in activity of some of the chemically 
modified variants (i.e. E192-HEBC and E192-HBC) compared to the wild-type protein.  
 
The majority of the E192 variants were tested with higher concentrations of ATOA in an 
attempt to evaluate their kinetic parameters in greater detail. A maximum concentration of 30 
mM of substrate was used to test the activity with the substrate ATOA. Even at these high 
concentrations of substrate, saturation of the enzyme was not approached. The specific 
activity (kcat/KM) could, however, be estimated for each enzyme. Figure 23 illustrates the 
activity of E192-ACEC and E192-PC in response to an increasing concentration of substrate 
ATOA (see appendix II for all other plots).    
 
Figure 23 | Two examples of the assessment of the kinetic parameters of the N-
acetylneuraminic acid analogue ATOA and SaNAL variants chemically modified at residue 
192. Left) The specific activity observed with E192-ACEC. Right) The specific activity observed 
with E192-PC. Even at concentrations of 30 mM of ATOA, saturation was not reached. 
 
Figure 24 shows all of the estimated kcat/KM values calculated. When compared to the kcat/KM of 
either N-acetylneuraminic acid with wild type SaNAL (52 min-1mM-1) or DPAH with the SaNAL 
variant E192N (33 min-1 mM-1) the results are clearly low. However, it would appear that subtle 
effects on the catalysis of the cleavage of truncated N-acetylneuraminic acid analogue ATOA 
has resulted from chemical modification of residue 192, though none of the chemically 
modified variants were more active than E192C. Out of the four best chemically modified 
variants of SaNAL, E192-CMC, E192-ACEC and E192-HBC possess hydrogen donor and acceptor 
properties which may be capable of forming the predicted interactions seen in Figure 21. 
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Unexpectedly, the variant E192-CPC also exhibited a specific activity (kcat/KM) that was 
comparable to E192-CMC, E192-ACEC and E192-HBC. 
 
Figure 24 | Estimated kcat/KM values for some of the E192X variants. The values are estimated 
by consideration of the gradient of specific activity against concentration of ATOA. Each 
measurement taken for obtaining these results was performed using 0.1 mg/mL of protein and 
a concentration of ATOA ranging from 0 mM to 30 mM.  
 
These studies have shown that the modified active site represented in Figure 21 is an 
oversimplification of the effects of chemical modification of active site residues on the 
recognition of the truncated N-acetylneuraminic acid analogue ATOA. However, the chemical 
modification of other residues within the active site of SaNAL may have a greater impact on 
the catalysis of the truncated N-acetylneuraminic acid analogue ATOA.   
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3.1.4 Kinetic characterisation of SaNAL variants, chemically modified at position 190, with a 
truncated N-acetylneuraminic acid analogue as a substrate  
 
Parallel research into the effects of the chemical modification of the active site of SaNAL by 
Claire Windle (University of Leeds) has resulted in the SaNAL variant F190-DHPC. This variant is 
capable of catalysing the forward aldol reaction between erythrose and pyruvate to yield the 
sugar 72 in a more efficient manner than the wild type protein, SaNAL (Scheme 30). In these 
studies, the concentration of product formed was determined using an established end-point 
assay.79,80 
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Scheme 30 | An F190-DHPC modified SaNAL protein capable of the catalysis of the forward 
aldol reaction of erythrose and pyruvate. The variant F190-DHPC was determined to be more 
efficient than SaNAL at catalysing the forward aldol reaction with these substrates. The 
concentration of product formed was established using an end point assay.79,80 
 
The N-acetylneuraminic acid analogue 72 is comparable to the N-acetylneuraminic acid 
analogue ATOA in both length and functionality (Figure 25). Both sugars are seven carbons 
long although the configuration and substitution at C-5 is different. 
 
 
Figure 25 | The truncated N-acetylneuraminic acid analogue 72 compared to the N-
acetylneuraminic acid analogue ATOA. The two sugars differ in functionality at carbon C-5 and 
configuration. Unlike compound 72, ATOA contains a single epimer at position C-3. 
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The activity observed with the chemically modified variant F190-DHPC in the condensation of 
erythrose and pyruvate results from the replacement of an aromatic residue at position F190 
(Figure 26) with an unnatural residue possessing polar functionality. Figure 26 illustrates the 
SaNAL enzyme with pyruvate covalently bound at residue K165. Also highlighted are the 
residues F190 and E192. Upon chemical modification of F190, newly introduced hydrogen 
bonding may stabilise the erythrose molecule, allowing recognition and cleavage of the 
truncated substrate 72.  
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Figure 26 | Proposed basis for the catalysis of the aldol reaction of a truncated N-
acetylneuraminic acid analogue by a chemically modified aldolase. A) Structure of the active 
site of SaNAL (from two viewpoints) highlighting positions K165, covalently bound with 
pyruvate, F190 and E192. B) Proposed representation of the active site of SaNAL in complex 
with erythrose (left) of the F190-DHPC variant of SaNAL in complex with erythrose (right). 
These models assume that erythrose binds to the active site of F190-DHPC in a similar manner 
to N-acetylneuraminic acid binding to E. coli NAL. (A) was generated using PyMOL (PDB file 
4AH7).78 
B 
A 
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3.1.5 Evaluation of the catalytic ability of SaNAL variants, chemically modified at position 
190, with the truncated N-acetylneuraminic acid analogue ATOA as a substrate 
 
As activity of the variant F190-DHPC was observed with a truncated N-acetylneuraminic acid 
analogue 72, four SaNAL variants chemically modified at position 190 were prepared (Figure 
27). The variants F190-HBC and F190-HPC were chosen as they contain hydroxyl groups similar 
to the variant F190-DHPC. The variant F190-PC was also chosen as an alternative to the 
hydroxyl functionality. These variants were then used in single concentration kinetic 
measurements with the N-acetylneuraminic acid analogue ATOA as substrate.  
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Figure 27 | The side chain of SaNAL variants chemically modified at position 190. The 
variants F190-DHPC, F190-PC and F190-HPC contain hydroxyl groups. The variant F190-PC was 
chosen as a non-polar alternative to this functionality. 
 
Kinetic measurements were taken over a one minute period and were performed using 0.1 
mg/mL of modified protein and 5 mM of the N-acetylneuraminic acid analogue ATOA. The 
results of these experiments can be seen in Figure 28. 
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Figure 28 | The single concentration kinetic measurements performed using the truncated N-
acetylneuraminic acid analogue ATOA. A) The uncorrected change in absorbance observed 
over the period of 1 minute. Each measurement was performed using 5 mM of ATOA and 0.1 
mg/mL of modified protein. B)  The unnatural amino acid side chains of chemically modified 
proteins used in the assay. C) The background change in absorbance observed over 1 min. 
These measurements are the sum of two control experiments: (i) with 5 mM of substrate in 
the cell and no aldolase, and (ii) with 0.1 mg/mL of protein and no substrate.  D) The 
background corrected change in absorbance observed over one minute. 
 
Unfortunately, no significant activity was observed with any of the four chemically modified 
enzymes. This result contrasts with the observation that the SaNAL variant F190-DHPC is able 
to catalyse the forward aldol reaction between pyruvate and erythrose to give the truncated 
N-acetylneuraminic acid analogue 72 (Claire Windle, University of Leeds). It can be concluded 
that the difference in activity observed between the N-acetylneuraminic acid analogues ATOA 
and 5 could stem from the difference in configuration of the substrates, the functionality at C-
5 or a combination of both factors. 
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3.1.6 Kinetic characterisation of SaNAL variants, chemically modified at position 190, with an 
enantiomeric truncated N-acetylneuraminic acid analogue as a substrate 
 
The molecule ent-ATOA (Figure 29) was synthesised to investigate the effects of configuration 
of the molecule on catalysis of the retro-aldol reaction. If the stereochemical configuration of 
the molecule was a major determinant in the turn-over of substrate then the molecule, ent-
ATOA might be cleaved by at least one of the SaNAL variants chemically modified at residue 
190.  
 
 
Figure 29 | Comparison of three truncated N-acetylneuraminic acid analogues. ATOA 
contains the same stereochemical configuration and functionality as N-acetylneuraminic acid. 
The analogue 72 (the product of the forward reaction with erythrose and pyruvate catalysed 
by the SaNAL variant F190-TG (see section 3.1.4) differs in stereochemical configuration and 
functionality at C-5. The analogue ent- ATOA is the enantiomer of the compound ATOA. 
 
Single kinetic measurements were performed with ent-ATOA using 0.1 mg/mL of modified 
protein and 5 mM of the truncated N-acetylneuraminic acid analogue ent-ATOA. The results of 
these measurements can be seen in Figure 30. 
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Figure 30 | The single concentration kinetic measurements performed using the truncated N-
acetylneuraminic acid analogue ent-ATOA. A) The uncorrected change in absorbance 
observed over the period of 1 minute. Each measurement was performed using 5 mM of ent-
ATOA and 0.1 mg/mL of modified protein. B) The unnatural amino acid side chains of 
chemically modified proteins used in the assay. C) The background change in absorbance 
observed over 1 min. These measurements were taken using 0.1 mg/mL of aldolase and no 
substrate.  D) The background corrected change in absorbance observed over one minute. 
 
As with the measurements performed with the truncated N-acetylneuraminic acid analogue 
ATOA, there is no substantial activity with any of the SaNAL variants tested. The conclusion, 
therefore, is that the lack of catalysis seen with this molecule relative to results seen with the 
truncated N-acetylneuraminic acid analogue 72 and the chemically modified SaNAL variant 
F190-DHPC (Claire Windle, University of Leeds) is not only a result of the stereochemical 
configuration of the molecule. The catalysis of the truncated N-acetylneuraminic acid analogue 
must therefore have a strong relationship with the C-5 hydroxyl.  The C-5 hydroxyl substituent 
in the substrate 72 must be a key determinant in the catalysis of the cleavage of the truncated 
substrate. 
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Figure 31 | Proposed interactions of the N-acetylneuraminic acid analogue 72. A) The binding 
site of SaNAL (cyan) overlaid with the E. coli NAL variant Y127A (light orange) in complex with 
N-acetylneuraminic acid (purple). Highlighted are the residues S48 and S49 along with the C-5 
NHAc functional group of N-acetylneuraminic acid. B) A schematic of possible hydrogen 
bonding between an SaNAL variant and the truncated N-acetylneuraminic acid analogue 72. 
Hydrogen bonding may occur between the residues S48, S49 and the alcohol at C-5. This 
hydrogen bonding may not be possible with the NHAc group of ent-ATOA. This figure assumes 
the same binding conformation of N-acetylneuraminic acid. The alcohol C-5 of the substrate 72 
may be around 4 Å from the alcohol residues S48 and S49. (A) was generated using PyMOL 
(PDB files 4AH7 and 4BWL).15,78 
 
The crystal structure in Figure 31 shows two serine side chains at positions 48 and 49. It may 
be possible that the side chains at residue 48 and 49 are able to form stabilising interactions 
with the C-5 hydroxyl group of the N-acetylneuraminic acid analogue 72 which are not possible 
with the truncated analogues ATOA and ent-ATOA. 15,78 
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3.2 Kinetic characterisation of the SaNAL variants, chemically modified at 
residue 192, with the substrate N-acetylneuraminic acid as a substrate 
  
An obvious line of investigation was the study of the effects of chemical modification at 
position 192 of SaNAL on activity with the natural substrate, N-acetylneuraminic acid. Previous 
studies of the E192X saturation mutagenesis library against N-acetylneuraminic acid using 
single concentration kinetic measurements had been performed (Amanda Bolt, University of 
Leeds), Figure 32. 87 The results of these measurements highlighted residue 192 as a highly 
relevant residue for the catalysis of the cleavage of N-acetylneuraminic acid. Changes at 
residue E192 resulted in a dramatic reduction in the turnover of N-acetylneuraminic acid with 
the exception of the mutant E192Q, Figure 32. It is therefore clear that the length and nature 
of the side chain at position 192 is crucial in the recognition of the substrate. 
 
Figure 32 | Catalysis of E192X variants observed with 0.5 mM of the substrate N-
acetylneuraminic acid and 0.03 mg/ml of enzyme. The change in absorbance was measured 
over 1 minute. Adapted from  87. 
 
The observation that E192 is an important residue for the catalysis of N-acetylneuraminic acid 
can be rationalised structurally. The crystal structure of Haemophilus influenza NAL in complex 
with the inhibitor 4-oxo-sialic acid implicates hydrogen bonding between the two oxygen 
atoms of the side chain of the residue E192 and the alcohols on C-8 and C-9 of 4-oxo-sialic 
acid.88 This could also explain the observation of catalysis with E192Q and N-acetylneuraminic 
acid (Figure 33). The conclusion drawn was that catalysis of the cleavage of N-acetylneuraminic 
acid by NAL relies heavily on hydrogen bonding between the substrate and the side chain at 
HO
OH
OH
OH
NHAc
OH O
OH
O
27
A C D E F G H I K M N P Q R S T V W --
0.0
0.1
0.2
0.3
0.4
d
A
3
4
0
 n
m
 (
m
in
-1
)
Residue at position E192
 Activity of E192X
with sialic acid, 27
 
67 
 
position 192. Interactions at position 192 that lead to the cleavage of N-acetylneuraminic acid 
appear to require either an acid or an amide of the correct length (Figure 32). The shorter side 
chain variants of E. coli NAL, E192D and E192N, exhibited relatively little turnover of the 
reverse-aldol reaction of N-acetylneuraminic acid.   
 
 
Figure 33 | Complexes of aldolase variants.  Top) Structure of E.coli NAL in complex with the 
inhibitor 4-oxo-sialic acid, showing hydrogen bonding observed between the alcohols C-8 and 
C-9 of 4-oxo-sialic acid and the residue E192 and Bottom) Proposed interactions between the 
alcohols C-8 and C-9 of N-acetylneuraminic acid and the residue E192Q. These interactions 
may account for the activity of the variant enzyme E192Q with N-acetylneuraminic acid. 
Adapted from 87. 
 
The decision was made to broaden the investigation of the effects of modification of residue 
192 on the catalysis of N-acetylneuraminic acid by using unnatural amino acid side chains.  
Based on previous results, the hypothesis was that any chemical modification at residue 192 of 
SaNAL would likely result in a great reduction in the ability of the protein to catalyse the retro-
aldol reaction of N-acetylneuraminic acid. 
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3.2.1 Evaluation of the catalytic ability of SaNAL variants, chemically modified at position 
192, with the substrate N-acetylneuraminic acid 
 
Due to the abundance of the substrate N-acetylneuraminic acid, it was decided that full kinetic 
evaluation of each of the chemically modified proteins with this substrate was viable. The 
kinetic parameters kcat, KM and kcat/KM were therefore determined for all of the SaNAL variants 
that had been chemically modified at residue 192. The results of these experiments could then 
be compared to the kinetic parameters of SaNAL with N-acetylneuraminic acid, and the impact 
of the modifications at position 192 determined.  
 
The kinetic parameters for each variant were established by first measuring the rate of change 
in absorbance using a fixed amount of protein (0.1 mg/mL) and an increasing concentration of 
N-acetylneuraminic acid (up to 20 mM). The specific activity of the enzyme was calculated for 
each concentration of N-acetylneuraminic acid. Michaelis-Menten enzyme kinetics could then 
be established from the graph of the specific activity against substrate concentration (Figure 
34). 
 
Figure 34 | Activity plots of four SaNAL variants with the substrate N-acetylneuraminic acid. 
A) the wild-type protein SaNAL, B) the chemically modified protein E192-DHPC, C) the 
chemically modified protein E192-HEBC, D) the chemically modified protein E192-MCMC. 
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Table 2 shows the kcat, KM and kcat/KM values of N-acetylneuraminic acid with all SaNAL variants 
chemically modified at residue 192 in addition to wild-type SaNAL, and the two mutants E192N 
and E192C. It is clear that the kcat values of all of the SaNAL variants chemically modified at 
position 192 are very low in comparison to the wild-type enzyme and also show a greatly 
reduced level of activity compared to E192N and E192C. The kcat values for the chemically 
modified variants range from 8.8 min-1 (E192-CHC) to 28.4 min-1 (E192-MCMC) i.e. ~ 5 - 20% of 
that of SaNAL (166.7 min-1). In all but two cases (E192-DHPC and E192-HPC), the KM is at least 
double that of wild-type SaNAL (3.2 mM), with the highest KM value resulting from the 
chemically modified variant E192-AEC (17.8 mM). The low kcat values and the high KM values 
together result in a greatly reduced specific activity of all the chemically modified proteins in 
comparison to wild type SaNAL. These results are consistent with the prior knowledge that size 
and functional group at position 192 is important for recognition of the substrate N-
acetylneuraminic acid.  
 
Table 2 | Table of the kinetic parameters determined for each of the variants of SaNAL 
(chemically modified at residue 192) with N-acetylneuraminic acid. Also included are the 
kinetic parameters determined for the wild type protein SaNAL and the variants E192N and 
E192C. The errors for kcat and KM are fitting errors. 
 
  Kinetic parameters 
    kcat = min-1 KM = mM 
kcat/KM = min-1 
mM-1 
Protein 
variant 
NAL 166.7 + 9.8 3.2 + 0.5 52.1 
E192N 96.5 + 20.1 8.7 + 3.8 11.1 
E192C 41.1 + 6.8 8.6 + 2.8 4.8 
E192-CMC 16.7 + 1.1 11.1 + 1.6 1.5 
E192-DHPC 13.4 + 0.8 3.8 + 0.7 3.5 
E192-PC 9.04 + 1.6 9.5 + 3.2 1.1 
E192-CPC 11.16 + 1.5 7.6 + 2.1 1.5 
E192-AEC 25.7 + 3.6 17.8 + 4.3 1.4 
E192-ACEC 14.0 + 1.9 12.8 + 2.2 1.1 
E192-HEBC 11.4 + 1.5 12.8 + 3.4 0.9 
E192-MCMC 28.4 + 3.3 9.9 + 2.4 2.9 
E192-HPC 16.34 + 2.0 5.7 + 1.7 2.9 
E192-CHC 8.8 + 0.8 9.5 + 1.9 0.9 
E192-HBC 20.6 + 2.5 9.6 + 2.6 2.1 
E192-AMCEC 11.1 + 0.5 7.8 + 1.0 1.4 
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When comparing the kcat values of the unnatural variants it would appear that E192-AEC, E192-
MCMC and E192-HBC provide the best results. The lowest KM values were achieved by E192-
DHPC and also E192-HPC. This resulted in the three best unnaturally modified variants for 
catalysis of N-acetylneuraminic acid being determined as E192-DHPC, E192-MCMC and E192-
HPC. 
 
The results of the kcat/KM can be seen in Figure 35. The results achieved were as expected as 
replacement of the glutamic acid residue with any of the unnatural residues resulted in a ~50 
fold reduction in efficiency when compared to wild-type SaNAL.  
 
Figure 35 | kcat/KM (min-1 mM-1) for the SaNAL variants (chemically modified at residue 192) 
with the substrate N-acetylneuraminic acid.   
 
The results gained from investigation of the effects of the chemical modification of residue 192 
on the catalysis of the cleavage of N-acetylneuraminic acid confirm the importance of size on 
activity. All of the unnatural residues are large in comparison with E and Q. The large residues 
at position 192 may prevent efficient binding and cleavage of the substrate in the active site. 
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3.2.2 Kinetic characterisation of SaNAL variants, chemically modified at residue 190, with the 
substrate N-acetylneuraminic acid  
 
An investigation into the impact of varying residue F190 on the catalysis of the cleavage of N-
acetylneuraminic acid had not previously been performed. An assertion could be made that 
the phenyl group at position 190 has minimal interactions with the numerous hydrogen bond 
donors on N-acetylneuraminic acid (Figure 36), as the hydrophobic phenyl group resides above 
the plane of the bound N-acetylneuraminic acid. Though residue F190 most likely does not 
hydrogen bond with the substrate N-acetylneuraminic acid, it may provide a key role in 
defining the active site of SaNAL. 
 
If, unlike residue E192, residue F190 is not integral to the identification and catalysis of the 
cleavage of N-acetylneuraminic acid, chemical modification of residue 190 may not drastically 
diminish activity. Therefore, full kinetic parameters were determined for N-acetylneuraminic 
acid with the four SaNAL variants (F190-DHPC, F190-HPC, F190-HBC and F190-PC previously 
discussed in section 3.1.6) chemically modified at position 190. 
 
 
 
 
 
 
 
 
 
 
 
 
 
31+ 
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Figure 36 | Proposed binding of N-acetylneuraminic acid in the active site of SaNAL. A) The 
crystal structure of the E. coli. NAL Y137A variant (light orange) with full length N-
acetylneuraminic acid (purple) covalently bound to K165 was overlaid with the active site of 
SaNAL (cyan) and these crystal structures were used to propose the binding of N-
acetylneuraminic acid to the active site of SaNAL. B) Representation of some important 
interactions between the substrate N-acetylneuraminic acid and the SaNAL active site. It 
would appear that residue F190 does not directly interact with the substrate but may play a 
key role in defining the active site of SaNAL. (A) was generated using PyMOL (PDB file 4AH7 
and 4BWL).15,78  
 
 
 
 
 
 
A 
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3.2.3 Evaluation of the catalytic ability of SaNAL variants, chemically modified at position 
190, with the substrate N-acetylneuraminic acid 
 
Full kinetic parameters for the SaNAL variants chemically modified at residue 190 together 
with F190C were established using N-acetylneuraminic acid as the substrate. Measurements 
were performed using 0.1 mg/mL of protein and an increasing concentration of N-
acetylneuraminic acid ranging from 0 to 25 mM. Michaelis-Menten enzyme kinetics could then 
be established from the graph of the specific activity against substrate concentration (Figure 
37). 
 
Figure 37 | Activity plots of four SaNAL variants with the substrate N-acetylneuraminic acid. 
A) The site directed SaNAL variant F190C B) The chemically modified variant F190-DHPC C) The 
chemically modified variant F190-HPC D) The chemically modified variant F190-HBC. 
 
The results from these measurements can be seen in Table 3. All kcat/KM values were decreased 
in comparison to the wild-type protein but it would appear the larger F190-DHPC and F190-
HBC retarded catalysis more than the slightly shorter residues F190-PC and F190-HPC. The kcat 
parameters for the variants F190-DHPC and F190-HBC (48.4 + 5.2 min-1 and 44.0 + 4.0 min-1 
respectively) are roughly a third of the wild-type kcat value (166.7 min-1). Along with the 
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decreased kcat values, the KM values for both of the variants F190-DHPC (7.6 + 1.8 mM) and 
F190-HBC (6.3 + 1.4 mM) are > 2-fold that of SaNAL (3.2 + 0.5 mM). These factors result in a 
~10-fold reduction in specific activity when compared to wild-type SaNAL. The variants F190-
DHPC and F190-HBC are also less efficient in the catalysis of the cleavage of N-
acetylneuraminic acid when compared to the variant F190C. The comparable reduction in 
specific activity observed with the variants F190-DHPC and F190-HBC may stem from steric 
factors (being the two longest chemical modifications at this position) or perhaps from the 
electronic properties of the unnatural amino acid side chains, with both containing a terminal 
primary alcohol. This can be inferred as the two variants F190-DHPC and F190-HBC are ~3 fold 
more active than F190-PC and F190-HPC and, as well as being shorter, they contain no 
terminal alcohol. 
 
Both variants F190-PC and F190-HPC exhibit an improvement on catalysis when compared to 
the variant F190C. The variant F190-PC maintains the KM of 3.2 mM shown by wild-type SaNAL 
(3.2 mM) and suffering a relatively small decrease in kcat (72.4 + 5.4 min-1 compared with 166.7 
+ 9.8 min-1 of wild-type SaNAL). On the other hand, the variant F190-HPC suffers a relatively 
large reduction in kcat (39 + 1.35 min-1) but actually exhibits an improvement in KM (1.4 + 0.23 
mM) when compared to the wild-type SaNAL protein (3.2 + 0.5 mM). This results in a 
maintenance of ~ 50% of the specific activity of wild-type enzyme. The >2-fold decrease in KM 
may be a result of the secondary alcohol of F190-HPC providing extra stability to the N-
acetylneuraminic acid substrate in complex with the active site. 
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Table 3 | Table of the kinetic parameters determined for each of the variants of SaNAL 
chemically modified at residue 190 with N-acetylneuraminic acid. Also included are the 
kinetic parameters determined for the wild type protein SaNAL and the variants E192N and 
E192C. The errors for kcat and KM are fitting errors. 
  
kinetic parameters 
 
  
kcat   
(min-1) KM (mM) 
kcat/KM 
 (min-1 mM-1) 
SaNAL 
variant 
NAL 166.7 + 9.8 3.2 + 0.5 52.1 
E192N 96.5 + 20.1 8.7 + 3.8 11.1 
F190C 48.14 + 1.6 3.0 + 0.4 16.0 
F190-DHPC 48.4 + 5.2 7.6 + 1.8 6.4 
F190-HBC 44.0 + 4.0 6.3 + 1.4 7.0 
F190-PC 72.4 + 5.4 3.18 + 0.7 22.6 
F190-HPC 39.0 + 1.4 1.4 + 0.2 27.3 
 
Figure 38 summarises the kcat/KM values for the SaNAL variants chemically modified at position 
190, and the substrate N-acetylneuraminic acid. Broadly speaking it would appear that the 
effect of modification of residue 190 on the catalysis of the cleavage of N-acetylneuraminic 
acid is less dramatic than modification of the residue 192. Though the effect is less dramatic, it 
may appear that the larger residues observed with the modifications F190-DHPC and F190-HBC 
may retard catalysis more than the smaller F190-PC and F190-HPC. It is apparent that upon 
replacement of the residue F190 with the small hydrophobic group (F190-PC), activity is still 
somewhat maintained. Also interesting is the large change in catalysis observed between the 
variants F190-DHPC and F190-HPC as the variation between the two is relatively small, with 
only the terminal alcohol of F190-DHPC being the variant factor. 
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Figure 38 | kcat/KM (min-1 mM-1) for the SaNAL variants chemically modified at residue 190 
with the substrate N-acetylneuraminic acid.   
 
The preliminary results shown in Figure 38 indicate that further investigation into the chemical 
modification at position 190 of SaNAL may result in the introduction of interesting catalytic 
properties to the enzyme. These studies have supported the theory that modifications to the 
residue 190 would have a less detrimental effect on catalytic function of SaNAL than 
modification of the residue 192. Figure 39 shows possible reasons for the activities observed 
with the SaNAL variants F190-HPC and F190-PC.  
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Figure 39 | Hypothetical proposed structure of the active site of the SaNAL variants F190-
HPC and F190-PC in complex with the full length substrate N-acetylneuraminic acid.  The 
active site has been adapted from the crystal structure of the E. coli NAL variant Y137A and the 
amino acid at residue 190 has been replaced with the unnatural amino acid variants HPC and 
PC. Additional hydrogen bonding to the full length N-acetylneuraminic acid provided by the 
alcohol of the unnatural amino acid HPC may provide additional recognition of the substrate to 
the active site, resulting in a decrease in KM from wild type SaNAL. Conversely the unnatural 
amino acid PC has similar non-polar properties to the natural F190 residue. 
 
 
3.2.4 Kinetic characterisation of SaNAL variants, chemically modified at position 190, with 
the enantiomeric N-acetylneuraminic acid analogue as a substrate 
 
Twinned with the investigation into the effects of the configuration of substrate upon catalytic 
function of the enzyme seen in section 3.1.6, it was decided to investigate the catalytic 
function of the SaNAL variants with the enantiomer of N-acetylneuraminic acid ent-NANA. The 
assumption in this case was that catalytic function may be diminished due to the well-
established hydrogen bonding between the amino acids with SaNAL and the side chains of N-
acetylneuraminic acid (Figure 40).  
 
Figure 40 | Comparison of N-acetylneuraminic acid with the enantiomer ent-NANA. It may be 
expected that the SaNAL variants would be less efficient at catalysing the retro-aldol reaction 
with the enantiomer ent-NANA, as the change in configuration is too great.  
78 
 
Single concentration kinetic measurements were performed with ent-NANA using 0.1 mg/mL 
of modified protein and 0.5 mM of the truncated N-acetylneuraminic acid analogue ent-NANA. 
The results of these measurements can be seen in Figure 41. 
 
 
Figure 41 | Single concentration kinetic measurements performed using the enantiomeric N-
acetylneuraminic acid analogue, ent-NANA. A) The uncorrected change in absorbance 
observed over the period of 1 minute. Each measurement was performed using 0.5 mM of ent-
NANA and 0.1 mg/mL of modified protein. B) The unnatural amino acid side chains of 
chemically modified proteins used in the assay. C) The background change in absorbance, this 
measurement was taken using 0.1 mg/mL of aldolase and no substrate. D) The background 
corrected change in absorbance observed over one minute. 
 
There is little activity with any of the SaNAL variants with the enantiomer of N-
acetylneuraminic acid (ent-NANA). It is likely that such a drastic change in stereochemistry of 
the substrate would require much more protein engineering than changing one specific 
residue within the active site of a protein. The lack of activity is made more obvious when 
comparing the activity to any of the chemically modified SaNAL variants with N-
acetylneuraminic acid as the substrate. For instance F190-DHPC with N-acetylneuraminic acid 
as the substrate produced a change in absorbance of 0.4333 over the period of one minute 
using 0.1 mg/mL of F190-DHPC and 0.5 mM of N-acetylneuraminic acid.   
79 
 
3.3 Kinetic characterisation of SaNAL variants, chemically modified at residue 
192, with the substrate DPAH 
 
Previous studies of the E192X saturation mutagenesis library against the N-acetylneuraminic 
acid analogue DPAH using single concentration kinetic measurements had been performed, 
Figure 42.16 The change in absorbance was measured over 1 min with 0.5 mM of DPAH and 
0.03 mg of protein. Figure 42 demonstrates that the protein has a high tolerance for 
modification at position E192 with 7 out of the 18 variants producing a change in absorbance 
of > 0.1 over the 1 min period. The ability of several variants to accept the substrate contrasts 
sharply with the E. coli NAL E192X library and the substrate N-acetylneuraminic acid. 
 
Figure 42 | Single concentration kinetic with an E192X mutant library using 0.5 mM of 
substrate and 0.03 mg/mL of aldolase. Left) measurements observed with N-acetylneuraminic 
acid. Right) measurements observed with the N-acetylneuraminic acid analogue DPAH. Figure 
taken from 16. 
 
The increased promiscuity shown with the N-acetylneuraminic acid analogue DPAH highlights 
residue 192 as less integral to the recognition of the substrate than it is to the substrate N-
acetylneuraminic acid. This can be understood through the properties of the sugar DPAH. The 
substrate N-acetylneuraminic acid relies on hydrogen bonding between the carboxylic acid 
residue of E192 and the substrate. The N-acetylneuraminic acid analogue DPAH replaces the C-
8 and C-9 alcohols of the wild-type substrate with a much less polar di-propyl-amide. The di-
propyl functionality, therefore, is unable to form hydrogen bonding interactions with the 
carboxylic acid of E192. Instead (as determined by analysis of the crystal structure of the 
E192N variant of E. coli NAL in complex with a DPAH analogue) the hydrophobic propyl side 
chains orientate towards non-polar amino acid side chains (Figure 43). This lack of direct 
interaction may account for the promiscuity of DPAH with variants at position 192. 
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Figure 43 | The active site of the E. coli NAL variant E192N in complex with a DPAH analogue. 
A) Structure found in three of the four subunits of E192N. B) Structure found in one of the four 
subunits of the crystal structure of the E192N variant of E. coli NAL. Figure adapted from 16. 
 
It was therefore perceived that the unnatural SaNAL variants, chemically modified at position 
192 may exhibit the same promiscuous features demonstrated by the E. coli NAL saturation 
mutagenesis studies.  
 
3.3.1 Evaluation of the catalytic ability of SaNAL variants, chemically modified at residue 
192, with the substrate DPAH  
 
The full kinetic parameters of all of the SaNAL variants at position 192 using DPAH as a 
substrate were determined. The measurements were performed using a fixed amount of 
protein (0.1 mg/mL) and a range of DPAH concentrations (up to 10 mM). The specific activity 
for each measurement could be calculated and from this the Michaelis-Menten kinetic 
parameters could be established (Figure 44).  
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Figure 44 | Activity plots for four chemically modified SaNAL variants with the substrate 
DPAH. A) E192-AEC B) E192-PC C) E192-CHC D) E192-DHPC.  
 
From these activity plots (Figure 44), it was possible to obtain the kcat, KM and kcat/KM values 
(Michaelis-Menten parameters) for all variants of SaNAL (chemically modified at position 192) 
and compare them to wild-type SaNAL, along with the variants E192N and E192C. Table 4 
shows these kinetic parameters. The most notable observation from the table is that the 
kcat/kM results are, although lower than E192N in all cases, highly variable. The results for 
kcat/kM ranging from 2.2 min-1 mM-1 for the variant E192-CMC to 20.4 min-1 mM-1 for the variant 
E192-DHPC.  
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Table 4 | Table of the kinetic parameters determined for each of the variants of SaNAL 
chemically modified at residue 190 with the substrate DPAH.  Also included are the kinetic 
parameters for SaNAL and the variants E192N and E192C for comparison. The errors for kcat 
and KM are fitting errors. 
 
  Kinetic parameters 
    kcat = min-1 KM = mM 
kcat/KM = min-
1
 mM-1 
SaNAL 
variant  
NAL 24.8 + 1.1 5.2 + 0.6 4.8 
E192N 56.5 + 2.4 1.7 + 0.2 33.2 
E192C 28.2 + 1.4 2.3 + 0.4 12.6 
E192-CMC 12.9 + 0.6 5.9 + 0.7 2.2 
E192-DHPC 26.5 + 2.2 1.3 + 0.3 20.4 
E192-PC 23.7 + 2.1 3.5 + 0.8 6.8 
E192-CPC 15.3 + 1.4 1.5 + 0.4 10.2 
E192-AEC 23.7 + 2.1 3.6 + 0.8 6.6 
E192-ACEC 24.7 + 4.7 8.6 + 2.9 2.9 
E192-HEBC 16.4 + 2.1 1.9 + 0.6 8.6 
E192-MCMC 13.6 + 0.4 1.5 + 0.2 9.1 
E192-HPC 18.3 + 3.1 2.6 + 1.0 7.0 
E192-CHC 12.1 + 1.9 3.6 + 1.1 3.4 
E192-HBC 17.8 + 2.7 1.2 + 0.5 14.8 
E192-AMCEC 12.2 + 0.6 2.4 + 0.3 5.1 
 
 It was assumed that SaNAL with the N-acetylneuraminic acid analogue DPAH as the substrate 
would be tolerant to chemical modifications at position E192C. Table 4 confirms this, with 
many of the modifications maintaining catalysis with the N-acetylneuraminic acid analogue 
DPAH. The variants E192-DHPC in particular is able to maintain 60% of the specific activity 
(kcat/KM) of E192N and E192-HBC is able to maintain ~50% specific activity of E192N (Figure 45).   
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Figure 45 | The kcat/KM (min-1 mM-1) values for all variants of SaNAL chemically modified at 
position 192 with the substrate DPAH. For comparison the kcat/KM Values for SaNAL and the 
variants E192N and E192C are also included. 
 
Most of the unnatural variants of SaNAL chemically modified at position 192 exhibit higher 
kcat/KM values compared to the wild-type protein. When compared to wild-type SaNAL, the 
variants F190-HBC and F190-DHPC exhibit a 3- and 4-fold increase in specific activity with 
DPAH (respectively). Both these variants contain a relatively long side chain with a terminal 
primary alcohol, which may contribute to the increase in activity.  
 
It is possibly unsurprising that E192-CMC and E192-ACEC exhibit poor kinetic parameters with 
the substrate DPAH as they both contain a formal negative charge at pH7.4 much like the wild 
type E. coli NAL and the E. coli NAL variant E192D, tested in single point kinetic measurements 
(Figure 42). The side chains of E192-CMC and E192-ACEC are lengthened analogue of the 
amino acids D and E. It would appear that removing this negative charge improves the kinetic 
parameters of the protein towards the reverse aldol reaction of DPAH as shown by the methyl 
ester forms of E192-CMC and E192-ACEC. E192-MCMC (kcat/KM = 9.1 min-1 mM-1) exhibits a >4 
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fold improvement in specific activity than the acid variant E192-CMC (kcat/KM = 2.2 min-1 mM-1). 
Similarly the variant E192-AMCEC (kcat/KM = 5.1 min-1 mM-1) exhibits just under a 2 fold 
increase in specific activity compared to E192-ACEC (kcat/KM = 2.9 min-1 mM-1).   
 
Interestingly the variant E192-CPC (kcat/KM = 10.2 min-1 mM-1) exhibits a ~ 3-fold increase in 
specific activity relative to the variant E192-CHC (kcat/KM = 3.4 min-1 mM-1) containing a similar 
side chain. The increased size of E192-CHC may reduce the binding efficiency of DPAH to the 
NAL variant.  
 
Although the SaNAL variants chemically modified at residue 192 maintained catalytic function 
with the substrate DPAH, the functionality of the unnatural amino acids used may not be the 
best for the turnover of DPAH. For instance there are no amides in the library and two of the 
three polar side chains are cyclic, restricting movement and possibly blocking the substrate 
DPAH. Further research into the area may require the addition of more polar amino acid side 
chains at position 192. An interesting experiment would be the incorporation of the thiol 2-
Mercaptoacetamide into position 192, which would lead to a lengthened analogue of the 
amino acids N and Q.  
 
3.4 Conclusion 
 
This research has shown that the integrated biological and chemical methods of modification 
of SaNAL is a viable route for the incorporation of unnatural amino acid side chains into the 
protein. These chemically modified SaNAL variants exhibited varied catalytic activity in the 
retro-aldol reaction with the substrate N-acetylneuraminic acid and the four analogues ATOA, 
DPAH, ent-ATOA and ent-NANA.  
 
Chemical modifications at position 192 resulted in a sharp decrease in the catalysis of the 
retro-aldol reaction of the wild-type substrate N-acetylneuraminic acid. This result was 
unsurprising as Amanda Bolt (University of Leeds) had previously demonstrated both the 
importance of functionality and size of residue 192, of E.coli NAL, to the catalysis of the aldol 
reaction of N-acetylneuraminic acid. Interestingly, the chemical modification of residue 190 
resulted in more varied kinetic parameters with N-acetylneuraminic acid. Both the variants 
F190-HPC and F190-PC resulted in an enzyme capable of withholding catalytic function with 
the substrate N-acetylneuraminic acid.  
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As with previous findings (Amanda Bolt, University of Leeds), many of the variants of SaNAL 
(chemically modified at residue 192) displayed improved catalytic parameters in the retro-
aldol reaction of the N-acetylneuraminic acid analogue DPAH, relative to the wild-type SaNAL 
protein. This improvement in activity is likely a result of the replacement of the natural 
negative charge at residue 192.  
 
Unfortunately, no chemically modified variant of SaNAL was able to efficiently catalyse the 
retro-aldol of the truncated N-acetylneuraminic acid analogues ATOA and ent-ATOA. The 
catalysis of these substrates may be improved through the chemical modification of other 
residues within the active site of SaNAL.    
 
The engineering of aldolase enzymes able to accept unnatural substrates previously proved to 
be challenging. Now this work has shown that, using the methods developed within the Berry 
group (see Section 1.4.3), it is possible to incorporate a range of unnatural functionality into a 
specific position within the active site of SaNAL. With further investigation, this method may 
allow for the development of an enzyme capable of catalysing the retro-aldol reaction of 
unnatural substrates such as truncated substrates.  
 
3.5 Future work 
 
Class I aldolases carry out their function through an active-site catalytic lysine residue which, in 
the presence of a ketone, is able to form a reactive enamine species. Enamine species are also 
exploited in organic synthesis by organocatalysts such as proline (Scheme 31).89-91 MacMillan’s 
imidazolidine catalysts are also utilised in the catalysis of reactions with α,β-unsaturated 
carbonyl compounds, through reactive iminium intermediates (Scheme 32).92,93 There are no 
known examples of such iminium species in natural enzymes, however enzymes are able to 
exploit iminium species through post-translational modifications (section 1.2). 
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Scheme 31 | Two catalysts that exploit reactive enamine species. A) The Class I aldolase 
SaNAL. B) The amino acid proline can be used in organic synthesis to catalyse aldol reaction. 
Proline does this by forming a reactive enamine species and as well as providing a proton 
(from the carboxylic acid). 94 
 
An ambitious objective, exploiting chemically modified SaNAL variants, would be the alteration 
of the catalytic function of the protein, away from catalysis of the aldol reaction and toward 
unnatural iminium catalysis, such as Michael addition or Diels–Alder reactions (Scheme 32). 
One possible way to achieve this would be by replacing the catalytic lysine residue with a 
secondary amine derivative. This, twinned with the synthesis of α,β-unsaturated carbonyl 
compounds, has the potential to result in an iminium species such as Scheme 32. If successful, 
this approach could be utilised for the catalysis of Diels‒Alder and Michael addition reactions.  
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Scheme 32 | Reactions of α,β-unsaturated carbonyl compounds through an iminium 
intermediate. A) MacMillan organocatalysts have been utilised in the catalysis of reactions 
with α,β-unsaturated carbonyl compounds.93,95-97 B) Hypothetical modified NAL capable of 
activating α,β-unsaturated carbonyl compounds towards reactions such as the nucleophilic 
addition of indole or Diels–Alder reactions. Such reactions could be performed 
intermolecularly (as illustrated) or intramolecularly. 
 
Initial design of the α,β-unsaturated carbonyl compounds 73, 74 and 75 was based on the N-
acetylneuraminic acid analogue DPAH (Figure 46). As DPAH is able to tolerant changes in the 
active site of SaNAL, taking this general structure and using it as a scaffold for the synthesis of 
α,β-unsaturated carbonyl compounds appeared to be a plausible starting point.  
 
Figure 46 | Three α,β-unsaturated analogues of DPAH.  
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A variant of SaNAL, K165C/E192N, could be exploited to produce SaNAL variants containing a 
secondary amine at position of 165. The SaNAL variant E192N would also be included as it  
would allow for the exploitation of the hydrophobic pocket by the α,β-unsaturated carbonyl 
compounds. The variant K165C could be exploited by chemical modification for the 
introduction of amino acid side chains containing secondary amines (Scheme 33). 
 
 
Scheme 33 | Proposed method for the incorporation of secondary amine side chains into 
residue 165 of SaNAL. 
 
Incubation of the α,β-unsaturated carbonyl compounds in the presence of a 2nd amine 
containing variant of SaNAL followed by NaBH4 reduction and mass spectrometry analysis 
could be used to evaluate the presence of a Schiff base (Scheme 34).   
 
 
Scheme 34 | Proposed experiment to detect formation of an iminium species covalently 
bound to the active site. The incubation of an α,β-unsaturated carbonyl compound with a 2° 
amine variant of SaNAL, followed by treatment with sodium borohydride and mass 
spectrometry analysis could be used to detect the formation of an iminium species.   
89 
 
After the proof of principle reaction (Scheme 34), many further experiments could be 
undertaken, possibly resulting in unnatural enzymes being exploited for iminium catalysis. 
Synthesis of α,β-unsaturated carbonyl compounds 74 and 75 (Figure 46) has begun as well as 
the synthesis of some thiols with secondary amine components which could be exploited in 
this future work. For further detail on these routes of synthesis please see Appendix III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
Experimental 
4.1 General Biology experimental 
 
4.1.1 Bacterial strains and plasmids 
 
XL10-Gold (Stratagene)  
Genotype: TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
 
BL21-Gold (DE3) (Agilent Technologies) 
Genotype: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte 
 
The pK nanA_S.aureus-His6 (Ampr) plasmid was supplied by Nicole Timms (University of Leeds). 
The genes for the mutants E192C and F190C were supplied by Claire Windle (University of 
Leeds) in the form of glycerol stock solutions of XL10-Gold cells. 
 
4.1.2 Chemicals 
 
All chemicals purchased were of analytical grade, and (unless stated otherwise) were used 
without further purification. 2-Aminoethane thiol HCl, 2-mercapto ethanol, disodium 
phosphate, hydrogen chloride 37% solution, L-cysteine methyl ester HCl, mercaptoacetic acid 
salt and monosodium phosphate were purchased from Acros Organics. Ammonium acetate, 
ampicillin sodium salt, N,N-dimethylformamide (DMF), ethanol, glycerol, L-cysteine, methanol, 
sodium chloride and tris(hydroxymethyl)aminomethane (tris base) were purchased from Fisher 
Scientific. 1-Mercapto-2-propanol, 1-thioglycerol, 2-furamethane thiol, 4-mercapto-1-butanol, 
benzyl mercaptan, cyclohexane thiol, cyclopentane thiol, N,N,N′,N′-
tetramethylethylenediamine (TEMED), and nicotinamide adenine dinucleotide (NADH) were 
purchased from Sigma. 3-Mercapto-1-hexanol and sodium hydroxide were purchased from 
Alfa Aesar. 2-Propene-1-thiol, acrylamide: N,N’-methylenebisacrylamide 24:1 solution and 
sodium dodecyl sulfate (SDS) were purchased from Fluka. 3-Mercaptopropanoic acid and 
methyl thioglycolate were purchased from Aldrich. Lactate dehydrogenase was purchased 
from Roche. DNA size markers were purchased from Promega. Chelating Sepharose Fast 
Flow™ was purchased from GE Healthcare. Dithiothreitol (DTT) was purchased from 
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ForMedium. N-Acetylneuraminic acid was purchased from CarboSynth. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from Generon. Broad range protein marker was 
purchased from NEB. Agarose was purchased from Melford. 
The substrates ATOA, DPAH, ent-ATOA, ent-NANA and the dibromide compound 28 were 
synthesised by myself (section 4.2). 
 
Stock solution of ampicillin (50 mg/mL) was made up using distilled water, and was sterile-
filtered, then stored in 500 µL aliquots at -20 °C.  Stock solution of IPTG (50 mg/mL) was made 
up using distilled water, and was sterile-filtered, then stored in 1 mL aliquots at -20 °C.  
 
4.1.3 Aseptic techniques and sterilisation 
 
Aseptic techniques were employed where applicable, media was autoclaved at 121 °C and 20 
psi for 20 minutes before use. Filter-sterilisation was performed using 0.22 µm MiniSart® 
disposable filters (Sartourius AG). 
 
4.1.4 Bacterial media 
 
2×TY 
Tryptone (1.6% w/v), yeast extract (1% w/v), NaCl (0.5% w/v). 
 
2×TY-agar plates 
Tryptone (1.6% w/v), yeast extract (1% w/v), NaCl (0.5% w/v), agar (1.5% w/v). 
 
4.1.5 pH measurements 
 
pH measurements were performed using a Jenway 3020 pH meter calibrated according to the 
manufacturer’s instructions. 
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4.1.6 Centrifugation 
 
Centrifugation of solutions > 1.5 mL were performed using an Avanti® J-26XP centrifuge 
(Beckman Coulter). Centrifugation of solutions < 1.5 mL were performed using a desktop MSE 
micro centaur centrifuge (MSE). 
 
4.1.7 Culture growth 
 
DNA from glycerol stock solutions of XL10-Gold cells containing the pK nanA_S.aureus-His6 
(Ampr) plasmid (wild type and mutants) was transformed into BL21-Gold (DE3) cells for protein 
expression (section 4.1.10 followed by section 4.1.13). 
BL21-Gold (DE3) glycerol stock solutions of either SaNAL or the variants E192C, E192N and 
F190C were used to inoculate 5 mL 2×TY starter cultures supplemented with 50 µg/mL 
ampicillin. The starter cultures were incubated overnight in an orbital shaker-incubator (37 °C, 
200 rpm). 5 µL of the starter culture was then used to inoculate 5 mL 2×TY media 
supplemented with 50 µg/mL ampicillin. This was left to incubate for 8 h in an orbital shaker-
incubator (37 °C, 200 rpm). 10 mL of this 100 mL culture was then used to inoculate 1 L of 2xTY 
media supplemented with 50 µg/mL ampicillin. When the optical density of the culture at 600 
nm (OD600nm) reached 0.6, IPTG (100 µM final concentration) was added to induce protein 
expression. 
 
4.1.8 Glycerol stock solutions 
 
0.5 mL of a 5 mL starter culture and was added to 0.5 mL of sterile glycerol in a Nunc 
CryoTube™ vial (Thermo Fisher Scientific) and stored at -80 °C. 
Glycerol stock solutions were also donated by Claire Windle and Nicole Timms (University of 
Leeds). 
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4.1.9 Agarose gel electrophoresis 
 
Nucleic acids > 1.5 kb were resolved using 0.7 % (w/v) agarose gel electrophoresis and 
electrophoresed alongside a 1 kb DNA ladder. A photo of the gel could then be taken (using UV 
light) with an InGenius gel imager (Syngene). 
 
TAE buffer (1L of 10 x stock) 
48.4 g Tris base 
11.4 mL glacial acetic acid (17.4 M) 
3.7 g EDTA, disodium salt 
deionized water to 1L 
 
4.1.10 Plasmid DNA purification 
 
Wizard® plus SV minipreps DNA purification was used to purify DNA and was used in 
accordance with the manufacturers’ instructions.   
 
4.1.11 Site-Directed Mutagenesis 
 
Site-directed mutagenesis was carried out using a QuickChange® Lightning Mutagenesis Kit 
(Agilent) according to manufacturers’ instructions. Primers had been previously designed, by 
Nicole Timms (University of Leeds), and can be seen in the appendix. Following mutagenesis, 
and dpn1 digest of methylated DNA, transformation of the mutagenized DNA into XL10-Gold 
cells was performed. Purification of the plasmid DNA and sequencing (Beckman Coulter 
Genomics) confirmed that mutagenesis was successful. 
 
4.1.12 DNA sequencing 
 
DNA sequencing was provided by Beckman Coulter Genomics, sequencing using the primers 
‘pKK For’ and ‘pKK Rev’ (primers were provided by Beckman Coulter Genomics).  
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4.1.13 Transformation of XL10-Gold Ultracompetent Cells 
 
A 45 μL aliquot of XL10-Gold ultracompetent cells was thawed on ice. The cells were 
transferred to a pre-chilled 14 mL BD Falcon polypropylene round-bottom tube. 2 μL β-
mercaptoethanol was added to the cells, the contents swirled, then incubated for 10 mins. 1.5 
μL of DNA was then added to the cells and the solution incubated for 30 mins. The cells were 
then heat-pulsed at 42 °C for 30 seconds, followed by immediate incubation on ice for 2 mins. 
Preheated (42 °C) 2×TY media (0.5 mL) was added to the cells and the solution incubated for 1 
h at 37 °C with agitation at 225 rpm. The transformed cells were then plated on 2xTY-agar 
plates containing 50 µg/mL ampicillin, and incubated overnight at 37 °C. Single colonies were 
picked and grown in selection media overnight. These cells were then used to make up glycerol 
stock solutions. 
Transformation into BL21-Gold (DE3) cells follows the same procedure, with two amendments. 
No   β-mercaptoethanol was used, and the cells were heat-pulsed for only 20 seconds. 
 
4.1.14 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The SDS-PAGE gels were made up of both a ‘resolving gel’ and a ‘stacking gel’. The gels were 
set  between two glass plates. The ‘resolving gel’ was added to the plates first and covered 
with isopropanol until the gel had polymerised. At this point the isopropanol was removed and 
the polymerised ‘resolving gel’ was topped with ‘stacking gel’ and a 10- or 15-well comb. Upon 
complete polymerisation the gel could be used immediately or stored in moist lab roll and 
cling film at 4 °C for up to 1 week.  
 
Resolving gel: 
7,500 µL 30% (w/v) acrylamide 
3,750 µL 1.5 M Tris/HCl pH 8.8 
150 µL 10% (w/v) SDS 
3,500 µL H2O 
50 µL 25% (w/v) ammonium persulphate (freshly made and added last)  
5 µL TEMED (added last) 
 
Stacking gel: 
625 µL 30% (w/v) acrylamide 
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625 µL 1.0 M Tris/HCl pH 6.9 
50 µL 10% (w/v) SDS 
3,650 µL H2O 
50 µL 25% (w/v) ammonium persulphate (freshly made and added last)  
5 µL TEMED (added last) 
 
SDS running buffer: 
3 g Tris base 
14.4 g glycerol 
1 g SDS 
140 µL β-mercaptoethanol 
1 L with H2O 
 
Sample buffer: 
308.5 mg dithiothreitol 
400 mg SDS 
20 mg bromophenol blue 
2 mL glycerol 
50 mM Tris/HCl pH 6.8 up to 20 mL 
 
Protein samples were mixed with sample buffer 1:1 ratio and boiled for 5 min before loading 
onto a gel. One lane would be loaded with an NEB broad range protein marker. Electrophoresis 
was performed at 30-60 mA for 1 h. Samples were then stained with coomassie for a minimum 
of 1 h and then destained in deionised water for a minimum of 1 h. A photo of the gel could 
then be taken using an InGenius gel imager (Syngene). 
 
4.1.15 Nickel affinity Purification of His6-tagged proteins from E. coli 
 
Expressed His6-tagged proteins were purified by Chelating SepharoseTM fast flow resin, loaded 
with 0.2M NiCl2.  
Centrifugation of 1 L bacterial culture (12,000 × g for 20 min) provided a cell pellet. Growth 
medium was decanted off and the pellet re-suspended in 30 mL washing buffer via the use of a 
homogeniser. The re-suspended pellet was lysed using a TS series Benchtop Cell Disruptor 
(Constant Systems Ltd.). Centrifugation of the lysed cells (40,000 × g for 45 min at 4 °C) was 
followed by loading of the supernatant (containing the soluble protein) onto 5 mL of settled 
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Ni-NTA resin. The solution was agitated at 4 °C for 1h followed by centrifugation (2,200 × g for 
6 min at 4°C) and the supernatant decanted. The resin was then washed 4 times with 40 mL of 
washing buffer, each wash required centrifugation (2,200 × g for 6 min at 4 °C) and removal of 
the resulting supernatant. 20 mL of elution buffer was then added to the resin and the solution 
incubated for 30 min at 4 °C with agitation, followed by centrifugation (2,200 × g for 6 min at 4 
°C). The purified protein was then dialysed (section 4.1.16) in 50 mM Tris/HCl, followed by two 
rounds of dialysis into 20 mM ammonium acetate. The protein concentration was measured 
(section 4.1.17) and the protein split into 2.5, 5 or 10 mg aliquots. These aliquots were flash 
frozen (liquid nitrogen), then lyophilised, and the protein stored at -20 °C. 
Washing buffer: 
50 mM Tris/HCl pH7.4                           
20 mM Imidazole                                                                                              
0.5 M NaCl 
Elution buffer: 
50 mM Tris/HCl pH7.4                                                                     
0.5 M Imidazole                                                                                                
0.5 M NaCl    
 
4.1.16 Protein dialysis 
 
Proteins were dialysed in 20 mM Tris/HCl buffers. Dialysis tubing was supplied by Fisher 
Scientific Limited and had a molecular weight cut off of 10 kDa. The volume of dialysis buffer 
was 1000 times that of the solution being dialysed. Each dialysis involved two rounds of gentle 
stirring of the dialysis buffer at 4 °C for 4 h.  
 
4.1.17 Determination of protein concentration  
 
Protein concentration was determined using the Beer‒Lambert law measuring at 280nm, or 
using a Bradford assay which involved incubating (> 5 mins) 980 µL Bradford reagent with 2µL 
protein solution and 18 µL buffer, and measuring the absorbance at 595 nm.  
97 
 
A Kontron Uvicon 930 spectrophotometer was used to measure absorbance values. Bovine 
serum albumin (BSA) was used as a standard for Bradford assays. 
 
4.1.18 Increasing protein concentration 
 
Protein concentration could be increased using Vivaspin 20 mL centrifugal concentrators 
(according to the manufacturer’s instruction). The concentrator tubes were equilibrated with 
water followed by the appropriate buffer before use (according to the manufacturer’s 
instruction).   
 
4.1.19 Mass spectrometry 
 
Mass spectrometry samples were suspended in 20 – 50 mM ammonium acetate. Buffer 
exchange of samples into ammonium acetate was achieved using Micro Bio-spinTM 
chromatography columns (Bio-Rad Laboratories). The columns were first equilibrated 
according to manufacturers’ instructions. Protein mass spectrometry was then performed on 
these samples by Dr. James Ault (University of Leeds) according to the following specification: 
Nanoelectrospray mass spectrometry was performed using a quadrupole-ion mobility 
spectrometry-orthogonal time-of-flight (TOF) mass spectrometer (Synapt HDMS, Water UK 
Ltd.). Positive electrospray ionisation was used. The mass spectrometer was operated in 
positive TOF ‘V’ mode using a capillary voltage of 1.2 kV, cone voltage of 50 V, 
nanoelectrospray nitrogen gas pressure of 0.1 bar and backing pressure of 1.78 mbar. The 
source and desolvation temperatures were set at 80 °C and 150 °C, respectively. Nitrogen was 
used as buffer gas at a pressure of 8.0 × 10-3 mbar in the trap and transfer regions, and 3.6 × 
10-4 mbar in the ion-mobility spectrometry (IMS) cell. Mass calibration was performed by a 
separate injection of sodium iodide at a concentration of 2 mg/mL in acetonitrile:water (1:1; 
v/v). Data processing, including deconvolution of multiple mass-charge state spectra, was 
performed using MassLynx v4.1 software (provided with the mass spectrometer). 
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4.1.20 Lyophilisation 
 
Solutions were flash-frozen using liquid nitrogen. Lyophilisation was achieved using a Heto 
PowerDry PL3000 Freeze Dryer, and a ThermoSavant VLP120 ValuPump. 
 
4.1.21 Lactate dehydrogenase coupled enzyme assay 
 
Kinetic measurements of the aldol cleavage reaction were performed using a standard lactate 
dehydrogenase (LDH) coupled reaction (Scheme 35).  
 
Scheme 35 | Coupled enzyme assay used for measuring the kinetic parameters of SaNAL. 
 
The measurements were undertaken in a Tris/ HCl pH7.4 buffer at 30 °C. Each solution 
consisted of 0.5 units of LDH, 0.2 mM NADH, 0.03 or 0.1 mg/mL of aldolase enzyme, 0.0 – 4.5 
mM of substrate and the Tris/ HCl buffer making up the solution to 1 mL. Upon transfer to the 
1 mL cuvette the sample was inverted 4 times and transferred immediately to the absorbance 
spectrometer. Absorbance was measured at 340 nm over the period of 1 min. Kinetic 
parameters kcat, KM and kcat/KM were determined by non-linear regression analysis.  
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4.1.22 General Method for the chemical modification of the cysteine containing SaNAL 
variants E192C or F190C  
 
Lyophilised cysteine-containing variants of SaNAL (2.5 mg – 10 mg) were dissolved in 50 mM 
sodium phosphate buffer (pH 8.0) containing 6 M urea, resulting in a protein concentration of 
2 mg/mL. This solution was vortexed for 10 seconds. A 0.44M solution of the dibromide 
compound 28 in DMF was added (60 eq.) to the protein solution, and this solution was 
vortexed for 5 seconds and incubated with agitation (200 rpm) at 37 °C for 90 mins. A 0.85 M 
solution of thiol (100 eq) in 2 M Tris HCl, 0-7.5 % DMF (to aid solubility) was added to the 
reaction mixture and the solution was vortexed for 10 seconds, followed by incubation with 
agitation (200 rpm) at 37 °C for 120 mins. The reaction mixture was then dialysed (section 
4.1.16), into 50 mM sodium phosphate with 6 M urea (2 rounds of dialysis), 50 mM sodium 
phosphate (two rounds of dialysis), followed by at least 2 rounds of dialysis into 50 mM Tris 
HCl pH 7.4. The protein was then concentrated to a volume of > 2.5 mL (section 4.1.18), and 
concentrated protein was purified using size exclusion chromatography (50 mM Tris HCl buffer 
pH 7.4). The eluent was then concentrated (Section 4.1.18), the protein concentration was 
determined (section 4.1.17) and the protein stored at 4 °C ready for use in kinetic 
measurements. Protein was characterised by HR-MS (characterisation performed by Dr. James 
Ault, University of Leeds). Typically from a 10 mg conversion of protein you could expect ~2-4 
mg recovery of chemically modified protein. 
 
4.1.23 Refolding of modified variants 
 
During the chemical modification process the protein is unfolded due to the presence of 6 M 
urea. To refold the protein the solution is first dialysed twice against a buffer containing 50 
mM sodium phosphate pH 8.0, 6 M urea for 4 h at RT, and then twice more in a urea-free 
buffer.   
 
4.1.24 Size Exclusion Chromatography  
 
Gel filtration of proteins was performed using a Superdex S200 column attached to an ÄKTA 
prime at 4°C. The protein was eluted in 2 mL fractions using (degassed) 50 mM Tris phosphate 
(pH7.4) buffer.  
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4.2 Chemistry Experimental 
 
All non-aqueous reactions were carried out under an atmosphere of nitrogen.  Water-sensitive 
reactions were performed in oven-dried glassware cooled under nitrogen before use.  Solvents 
were removed under reduced pressure using a Büchi rotary evaporator and a Vacuubrand 
PC2001 Vario diaphragm pump. The removal of water was achieved by lyophilises using a 
VirTis benchtop K freeze dryer and a Vacuubrand PC2001 Vario diaphragm pump. 
 
Dry solvents were obtained using a solvent purification system (Innovative Technology Pure 
SolveTM).  Ether refers to diethyl ether and petrol refers to petroleum spirit (b.p. 40-60 C). 
N-Bromosuccinimide was recrystallised from water and dried under vacuum prior to use. All 
other solvents and reagents were of analytical grade and used as supplied.  Commercially 
available starting materials were obtained from Sigma–Aldrich, Lancaster, Alfa Aesar, 
Novabiochem, Carbosynth or Fluorous Technologies. 
 
Flash column chromatography was carried out using silica (35-70 μm particles) according to 
the method of Still, Kahn and Mitra. 98  Thin layer chromatography was carried out on 
commercially available pre-coated aluminium plates (Merck silica Kieselgel 60F254). 
 
Analytical LC-MS was performed using an Agilent 1200 series LC system comprising of a Bruker 
HCT Ultra ion trap mass spec, a high vacuum degasser, a binary pump, a high performance 
autosampler and micro well plate autosampler, an autosampler thermostat, a thermostated 
column compartment and diode array detector.  The system used two solvent systems: 
MeCN/H2O + 0.1% Formic acid with a Phenomenex Luna C18 50 x 2mm 5 micron column or. 
MeCN/H2O with a Phenomenex Luna C18 50 x 2mm 5 micron column. 
 
Proton and carbon NMR spectra were recorded on a Bruker Advance DPX300, Advance 500 or 
DRX500 spectrophotometer using an internal deuterium lock.  Carbon NMR spectra were 
recorded with composite pulse decoupling using the waltz 16 pulse sequence.  DEPT, COSY, 
HMQC and HMBC pulse sequences were routinely used to aid the assignment of spectra.  
Chemical shifts are quoted in parts per million downfield of tetramethylsilane, and coupling 
constants (J) are given in Hz.  NMR spectra were recorded at 300 K unless otherwise stated. 
 
Melting points were determined on a Reichert hot stage microscope and are uncorrected. 
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Nominal and accurate mass spectrometry using electrospray ionisation was carried out by staff 
in the School of Chemistry at the University of Leeds, using either a Micromass LCT-KA111 or 
Bruker MicroTOF mass spectrometer.   
 
Optical activity measurements were recorded at room temperature on an Electron Schmidt + 
Haensch Polartronic H532 polarimeter; units for [α]D are 10–1 deg cm2 g–1 and are omitted. 
 
Infrared spectra were recorded on a Perkin Elmer spectrum One FT-IR spectrophotometer.   
 
Ion exchange chromatography was performed using DOWEX 1X8, 200-400 mesh resin. 
 
DOWEX resins were activated (according to the suppliers guide lines) before use.  
 
Ozone was generated using a Welsbach T-816 generator (0.4-0.6 psi), and the reaction was 
purged before and after the reaction with oxygen gas (0.4-0.6 psi) for a minimum of 20 mins. 
 
Experimental Data: 
2,5-Dibromohexanediamide 28.99 
BrBrH2N
O O
NH2  
Adipic acid (5.23 g, 35.8 mmol) was added to thionyl chloride (15.0 mL, 207 mmol) and heated 
at reflux for 1.5 h, cooled to room temperature and CCl4 (20 mL), NBS (15.0 g, 84.3 mmol) and 
48% aqueous HBr (one drop) were added and solution heated at reflux for a further 4 h. The 
solution was then stirred at 0 °C for 30 mins, filtered, and the filtrate reduced in vacuo to give 
a crude red oil. The crude oil was added drop wise at 0 °C over a period of 20 min to a solution 
of 35 % aqueous NH4OH (40 mL) and left to stir for 1 h, filtered and reduced in vacuo. The 
crude solid was crystallised from H2O‒MeOH to yield the dibromide 28 (5.2 g, 50%) as large 
flake crystals; m.p. 192-194 °C (from H2O–MeOH) [lit.100 196 °C]; max/cm-1 (solid) 3188, 2947, 
2800 and 1666;  δH (500 MHz; DMSO) 7.71 (2H, s, NH2), 7.33 (2H, s, NH2), 4.38-4.28 (2H, m, 2 × 
CHBr), 2.08-1.75 (4H, m, CH2CH2); δC (75 MHz; DMSO) 169.81 (CO), 169.75 (CO), 48.45 (CHBr), 
48.17 (CHBr), 32.54 (CH2), 32.41 (CH2); m/z (ES) MNa+ 322.0 (50%), 324.9 (100%), 326.9 (50%); 
HRMS Found M+Na: 324.8993. C6H10Br2O2 requires M+Na, 324.8986. 
102 
 
 
(E)-N-(2-Ethoxy-2-oxoethylidene)-2-methylpropan-2-amine oxide 38. 81,101 
N
O
O
O
 
N-alkylhydroxylamine HCl (0.63 g, 5 mmol) and, 50% in toluene, ethyl glyoxylate solution (1.02 
g, 5 mmol,) were added to a solution of sodium bicarbonate (0.84 g 10 mmol) in toluene (10 
mL) and the reaction mixture was stirred at room temperature overnight. The solid was 
filtered and the filtrate was concentrated in vacuo to yield 38 (0.85 g, 98 %), with no further 
purification, as a pale yellow oil. Rf: 0.87 (9:1, DCM‒MeOH); max/cm-1 (film) 3392.17, 1724.07 
and 1624.55; δH (500 MHz; CD3OD) 7.25 (1H, s, 1-H), 4.23 (2H, q, J 7.1, ethyl 1-H), 1.51 (9H, s, 
tbutyl 2-H3), 1.29 (3H, t, J 7.1, ethyl 2-H3); δC (75 MHz; CD3OD) 160.7 (2-C), 121.3 (1-C), 74.6 
(ethyl 1-C), 60.7 (tbutyl 1-C), 28.1 (tbutyl 2-C), 14.1 (ethyl 2-C); HRMS Found M+H: 174.1126. 
C8H15NO3 requires M+H, 174.1125. 
 
Methyl-5-acetamido-4-hydroxy-2-methoxy-6-((7R,8R)-7,8,9-trihydroxypropyl)tetrahydro-2H-
pyran-2-carboxylate 42.82 
 
N-Acetylneuraminic acid (10 g, 32 mmol) and Dowex H+ resin (23 g) were stirred in MeOH (40 
ml) at reflux for 48 h. The reaction mixture was cooled to room temperature, filtered, reduced 
in vacuo to give the crude product which was recrystallised from MeOH–ether to yield the 
sugar 42 (5.2 g, 50 %) as large plate crystals, m.p. 59-60 °C (EtOAc–petrol); Rf: 0.67 (0.8:2:1, 
H2O–iPrOH–EtOAc); [α]D
20: −37.6  (c. 0.7 in MeOH); max/cm-1 (solid) 3600-3050, 2935, 1634 and 
1036; δH (500 MHz; D2O) 3.97 (1H, app. dt, J 10.2 and 5.1, 4-H), 3.87-3.74 (7H, m, 5-H, 6-H, 7-H, 
9-HA, and methyl ester Me), 3.59 (1H, dd, J 12.0 and 5.7, 9-HB), 3.51 (1H, app. d, J 9.6, 8-H), 
3.18 (3H, s, methyl ether 1-H3), 2.32 (1H, dd, J 13.1 and 5.1, 3-Heq), 1.97 (3H, s, acetyl Me), 1.71 
(1H, dd, J 13.1 and 10.2, 3-Hax); δC (75 MHz; D2O) 174.7 (methyl ester CO), 170.3 (acetyl CO), 
99.1 (2-C), 70.4, 69.7, 67.8 (8-C), 66.3 (4-C), 63.2 (9-C), 53.4 (methyl ester Me), 51.6, 50.9 
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(methyl ether Me), 39.1 (3-C), 22.0 (acetyl Me); HRMS Found M+Na: 360.1276, C13H23NO9 
requires M+Na, 360.1265.  
 
(2R,4S,5R,6R)-Methyl-5-acetamido-4-hydroxy-6-(hydroxymethyl)-2-methoxytetrahydro-2H-
pyran-2-carboxylate 46.82 
 
A solution of periodic acid (444 mg, 1.95 mmol) in water (25 mL) was added dropwise to a 
solution of Sugar 42 (250 mg, 0.74 mmol) in water (25 mL) over 10 min. The solution was 
stirred for a further 20 min at room temperature. The reaction mixture was then passed down 
a dowex 1X8 ion exchange column eluting with water (25 mL). The eluent was then reduced in 
vacuo and the resulting solid dissolved in methanol (5 mL) and cooled to 0 C. NaBH4 (64.7 mg, 
1.71 mmol) was added over 5 min and the solution stirred for 20 min. After which dowex H+ 
resin was added to achieve pH 6, the solution was filtered, washed with methanol (5 mL) and 
the filtrate was then passed through a dowex 1X8 resin eluting with methanol (20 mL). The 
eluent was reduced in vacuo to yield the alcohol 46 (190.0 mg 95%) as a pale yellow glass solid, 
[α]D
23: −39.4 (c. 0.9 in MeOH); max/cm-1 (solid) 3700-3100, 2895 and 1638; δH (500 MHz; D2O) 
3.93 (1H, ddd, J 11.6, 9.9 and 5.2, 4-H), 3.79 (3H, s, methyl ester Me), 3.74-3.51 (4H, m, 5-H, 6-
H and 7-H), 3.16 (3H, s, methyl ether Me), 2.33 (1H, dd, J 13.2 and 5.2, 3-Heq), 1.96 (3H, s, J 
1.96, acetyl Me), 1.71 (1H, dd, J 13.2 and 11.6, 3-Hax); δC (75 MHz; D2O) 174.7 (methyl ester 
CO), 170.0 (acetyl CO), 98.8 (2-C), 73.1 (6-C), 66.0 (4-C), 60.6 (7-C), 53.4 (methyl ester Me), 
51.8 (5-C), 50.7 (methyl ether Me), 39.0 (3-C), 21.9 (acetyl Me); HRMS Found M-H: 276.1099. 
C11N19NO7 requires M-H, 276.1089.  
 
(2R,4S,5R,6R)-5-Acetamido-2,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
carboxylic acid (ATOA).82 
 
Sugar 107 (131 mg, 0.47 mmol) was dissolved in an aqueous solution of 0.06 M NaOH (10.5 ml) 
and stirred for 3 h at room temperature. The solution was neutralised with Dowex H+ resin, 
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filtered, and the filtrate reduced in vacuo. The solid was then dissolved in an aqueous solution 
of 20 µM formic acid (2mL) and heated to 80 °C for 12 h. The solution was cooled and reduced 
in vacuo. The resulting solid was purified via mass directed chromatography to yield ATOA (55 
mg 61%) as a light yellow glass solid. [α]D
25: −36.4 (c. 0.1 in MeOH); max/cm-1 (Solid) 3600-3050 
and 1601; δH (500 MHz; D2O) 3.93 (1H, ddd, J 11.4, 9.9 and 4.8, H-4), 3.72 (1H, ddd, J 10.6, 4.8, 
and 2.7, H-6), 3.66 (1H, app. d, J 10.6, H-5), 3.59 (1H, app. d, J 2.7, H-7A), 3.58 (1H, app. d, J 4.8, 
H-7B), 2.17 (1H, dd, J 13.0 and 4.8, H-3eq), 1.98 (3H, s, acetyl 2-H3), 1.75 (1H, dd, J 13.0 and 11.4, 
H-3ax); δC (75 MHz; D2O) 176.4 (carboxyl CO), 170.6 (acetyl CO), 96.2 (2-C), 72.7 (6-C), 67.0 (4-
C), 61.1 (7-C), 52.5 (5-C), 29.5 (3-C), 22.1 (acetyl Me); HRMS Found M-H: 248.0776. C9H15NO7 
requires M-H, 248.0776.  
 
2,3-O-Isopropylidene-D-ribono-1,4-lactone 49. 76,102  
 
 
 
 
D-Ribono-1,4-lactone (15.0 g, 101 mmol) was added to a solution of conc. H2SO4 (12 mL) in 
acetone (750 mL) and stirred at room temperature for 12 h. The mixture was neutralised with 
solid sodium carbonate (60.0 g), dried (MgSO4), filtered and concentrated in vacuo to give a 
crude product which was recrystallised from EtOAc–petrol to yield the lactone 49 (13.4 g, 70%) 
as colourless plates; m.p. 136-138 °C (from EtOAc–petrol), [lit.76 137-139 oC]; Rf: 0.72 (1:1 
EtOAc–petrol); [α]D
20: −60.9 (c. 1.2 in MeOH) [lit.76 [α]D
20: −67.6 (c. 1.0 in CHCl3)]; max/cm-1 
(solid) 3501, 2990, 2950 and 1770; δH (500 MHz; CDCl3) 4.84 (1H, d, J 5.6, 2-H), 4.79 (1H, d, J 
5.6, 3-H), 4.64 (1H, app. t, J 1.8, 4-H), 4.01 (1H, ddd, J 12.3, 5.5, and 2.2, 5-HA), 3.82 (1H, ddd, J 
12.3, 5.5 and 1.7, 5-HB), 2.58 (1H, t, J 5.5, OH), 1.48 (3H, s, ipropyl MeA), 1.39 (3H, s, ipropyl 
MeB); δC (75 MHz; CDCl3) 175.4 (1-C), 113.1 (ipropyl 2-C), 83.3 (4-C), 78.3 (3-C), 75.7 (2-C), 61.8 
(5-C), 26.7 (ipropyl MeA), 25.4 (ipropyl MeB); HRMS Found M+Na: 211.0579. C8H12O5N requires 
M+Na, 211.0577. 
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5-Deoxy-5-iodo-2,3-O-isopropylidene-D-ribono-1,4-lactone 50. 76,102 
O O
I
O O
H H
 
The Lactone 49 (13.0 g, 69.2 mmol) was added to a solution of imidazole (14.3 g, 210 mmol) 
and triphenylphosphine (64.8 g, 199 mmol), in toluene (240 mL) and heated to 75 °C. Iodine 
(35.1 g, 138 mmol) was added in small portions over 10 min and the mixture left to stir for a 
further 30 min. The reaction was then cooled to room temperature, quenched with 1M 
aqueous sodium thiosulfate solution (120 mL), and extracted with ethyl acetate (3 × 120 mL). 
The combined organic layers were washed with brine (120 mL), dried (MgSO4), filtered and 
reduced in vacuo to give a crude product. Purification by column chromatography (gradient 
elution 5:95 → 50:50 EtOAc–petrol) gave the lactone 50 (12.9 g, 68%) as colourless needles, 
m.p. 96-97 °C (EtOAc–Petrol), [lit.76 89-91 °C]; Rf: 0.36 (1:9 EtOAc–Petrol); [α]D
20: −20.4 (c. 1.7 in 
MeOH), [lit.76 −31.0 (c. 0.9 in CHCl3)]; max/cm-1 (solid) 2992 and 1770; δH (500 MHz; CDCl3) 
4.98 (1H, d, J 6.1, 2-H), 4.63 (1H, dd, J 5.3 and 3.2, 4-H), 4.61 (1H, d, J 6.1, 3-H), 3.44 (1H, dd, J 
11.2 and 3.2, 5-HA), 3.39 (1H, dd, J 11.2 and 5.3, 5-HB), 1.48 (3H, s, ipropyl MeA), 1.40 (3H, s, 
ipropyl MeB); δC (75 MHz; CDCl3) 173.1 (1-C), 114.1 (ipropyl 2-C), 80.9 (4-C), 80.4 (3-C), 77.2 (2-
C), 27.0 (Ipropyl MeA), 26.5 (ipropyl MeB), 5.6 (5-C); m/z (ES) 618.9 (100%, 2M+Na). 
 
 
(2R, 3R)-2,3-O-Isopropylidene-pent-4-enoic acid 51. 76,102 
 
 
Zinc/copper couple (22.7 g) was added to a solution of the lactone 50 (13.0 g, 47.3 mmol) in 
4:1 acetone–water (100 mL) and the resulting mixture was stirred at reflux for 2 h. The 
reaction mixture was cooled, filtered through celite, washing with acetone, and the filtrate 
concentrated in vacuo. The residue was redissolved in chloroform (80 mL) containing formic 
acid (2.2 mL) and washed with brine (65 mL). The aqueous phase was re-extracted with 
chloroform (4 × 35 mL), the combined organic layers were dried (NaSO4), filtered and 
evaporated in vacuo to give the acid 51 (6.3 g, 77%) as a colourless oil. Rf: 0.5 (99:1 EtOAC–
AcOH); [α]D
25: −31.3 (c. 0.8 in MeOH), [lit.76 −24.6 (c. 1.56 in CHCl3)]; max/cm-1  (film) 3600-
2800 and 2990; δH (500 MHz; CDCl3) 9.68 (1H, s, CO2H), 5.47 (1H, ddd, J 17.2, 10.5 and 7.0, 4-
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H), 5.48 (1H, d, J 17.2, 5-Htrans), 5.32 (1H, d, J 10.5, 5-Hcis), 4.86 (1H, app t, J 7.2, 3-H), 4.70 (1H, 
d, J 7.2, 2-H), 1.63 (3H, s, ipropyl MeA), 1.42 (3H, s, ipropyl MeB); δC (75 MHz; CDCl3) 174.6 (1-C), 
131.6 (4-C), 120.0 (5-C), 111.4 (ipropyl 2-C), 78.6 (3-C), 77.2 (2-C), 26.8 (ipropyl MeA), 25.4 
(ipropyl MeB); HRMS Found M+Na: 195.0636, C8H12O4 requires M+Na, 195.0628. 
 
(2R, 3R)-2,3-O-Isopropylidenepent-4-enoic acid dipropylamide 52. 76,102 
 
The carboxylic acid 51 (3.00 g, 17.3 mmol) was added to a solution of EDC (4.99g, 26.0 mmol), 
HOBt (3.51 g, 26.0 mmol) and dipropylamine (3.56 mL, 26.0 mmol) in EtOAc (600 mL), and the 
resulting mixture stirred at room temperature for 16 h. The reaction mixture was washed with 
water (400 mL), the aqueous phase extracted with EtOAc (2 × 300 mL), dried (MgSO4) and 
concentrated in vacuo to give a crude product. Purification by column chromatography (1:1 
EtOAc–petrol) gave the dipropylamide 52 (6.3 g, 69%) as a pale yellow oil. Rf: 0.31 (1:2 EtOAc–
petrol); [α]D
20: −13.8 (c. 0.9 in MeOH) [lit.76 −28.6 (c.0.91 in CHCl3)]; max/cm-1 (solid) 2965, 
2936, 2876 and 1660; δH (500 MHz; CDCl3) 5.80 (1H, ddd, J 17.4, 10.2 and 8.2, 4-H), 5.40 (1H, d, 
J 17.4, 5-Htrans), 5.25 (1H, d, J 10.2, 5-Hcis), 4.94 (1H, d, J 7.2, 2-H), 4.78 (1H, app. t, J 7.8, 3-H), 
3.50 (1H, dt, J 13.4 and 7.7, propyl 1-H), 3.15 - 2.96 (3H, m, 3 × propyl 1-H), 1.66 (3H, s, MeA), 
1.65 - 1.74 (4H, m, 2 × propyl 2-H2), 1.41 (3H, s, MeB), 0.91 (3H, t, J 7.4, propyl 3-H3), 0.88 (3H, 
t, J 7.4, propyl 3-H3); δC (75 MHz; CDCl3) 167.5 (1-C), 133.8 (4-C), 119.9 (5-C), 110.7 (ipropyl 2-
C), 79.4 (3-C), 75.6 (2-C), 49.0 (propyl 1-C), 48.2 (propyl 1-C), 26.8 (ipropyl MeA), 25.5 (ipropyl 
MeB), 22.2 (propyl 2-C), 20.7 (propyl 2-C), 11.5 (propyl 3-C), 11.2 (propyl 3-C); HRMS Found 
M+H: 256.1910, C14H25NO3 requires M+H, 256.1907. 
 
 (2R,3R)-2,3-Dihydroxy-N,N-dipropylpent-4-enamide 53. 76,102 
 
The dipropylamide 52 (3.0 g, 12 mmol) was dissolved in 9:1 trifluoroacetic acid–water (25 mL) 
and stirred for 2 min. The reaction mixture was concentrated in vacuo to give a crude product. 
Purification by column chromatography (2:3 EtOAc–petrol) gave the dihydroxyamide 53 (2.3 g, 
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92%) as a colourless amorphous solid; m.p. 75–77 °C (EtOAc–petrol) [lit.76 77–79 °C  (CH2Cl2)]; 
Rf: 0.33 (1:1 EtOAc–petrol); [α]D
20: +9.8 º (c. 1.2 in MeOH) [lit.76 [α]D
20 +17.1 (c. 0.84 in CHCl3)]; 
max/cm-1 (solid) 3325, 2966, 2877 and 1621; δH (500 MHz; CDCl3) 5.81 (1H, ddd, J 17.0, 10.6 
and 5.6, 4-H), 5.34 (1H, d, J 17.0, 5-Htrans), 5.26 (1H, d, J 10.6, 5-Hcis), 4.44 (1H, d, J 4.1, 2-H), 
4.23 (1H, dd, J 5.6 and 4.1, 3-H), 3.58 (1H, ddd, J 13.6, 8.6 and 6.8, propyl 1-H), 3.36 (1H, ddd, J 
15.6, 8.3 and 7.3, propyl 1-H), 3.16 (1H, ddd, J 14.8, 8.6 and 6.1, propyl 1-H), 3.05 (1H, ddd, J 
15.6, 8.3 and 7.0, propyl 1-H), 1.70 - 1.50 (4H, m, 2 × propyl 2-H2), 0.94 (3H, t, J 7.4, propyl 3-
H3), 0.90 (3H, t, J 7.4, propyl 3-H3); δC (75 MHz; CDCl3) 171.3 (1-C), 135.4 (4-C), 117.5 (5-C), 73.9 
(3-C), 70.6 (2-C), 48.8 (propyl 1-C), 47.6 (propyl 1-C), 22.1 (propyl 2-C), 20.6 (propyl 2-C), 11.3 
(propyl 3-C), 11.1 (propyl 3-C); m/z  (ES) 238.1 (30.2%,  M+Na). 
 
(5R,6R)-7-(Dipropylamino)-4,5,6-trihydroxy-2,7-dioxoheptanoic acid (DPAH).71,83 
NPr2
OOH
OHOHO
HO
O  
The alkene 53 (1.16 g, 5.3 mmol) was dissolved in methanol (20 mL) and cooled to -78 °C, 
oxygen was bubbled through the solution for 20 min and then O3 was bubbled through the 
solution until a blue colour was observed, at which point oxygen was bubbled through the 
solution for 20 min. Dimethyl sulfide (0.85 mL, 25 mmol) was added to the reaction mixture 
and the mixture stirred at room temperature until a negative ozonide test was observed 
(starch iodine paper). The reaction was reduced in vacuo. The residue was re-suspended in 20 
mM Tris HCl buffer pH 7.4 (37 mL). Sodium pyruvate (3.3 g, 30 mmol) was added, the pH 
corrected to pH 7.4, the enzyme E192N (3 mg/mL, 3 mL) was added and the reaction mixture 
stirred for 18 h. Aqueous formic acid (2M) was added to achieve pH 3 and the solution was 
stirred for 15 min, the pH was adjusted to pH 7 with aqueous ammonium hydroxide (2M) and 
baker’s yeast was added (5 g) and the reaction stirred for 18 h. The emulsion was filtered 
through celite, pad washed with water (10 mL) and the filtrated was lyophilised. The crude 
product was re-suspended in water (3 mL) and purified via ion exchange chromatography to 
yield the sugar DPAH in (0.9 g, 60 %) as a colourless glass,  Rf: 0.5 (5:2:2, EtOAc‒AcOH‒H2O);  
max/cm-1 (solid) 3119, 2966, 2936, 2877, 1715 and 1621; δH (500 MHz; D2O) 4.66 (1H, d, J 9.5, 
6-H (maj fur)), 4.01 (1H, ddd, J 11.8, 9.5 and 5.1, 4-H (maj fur)), 3.74 (1H, t, J 9.5, 5-H (maj fur)), 3.58-
3.40 (2H, m, propyl 1-H2), 3.38- 3.19 (2H, m, propyl 1-H2), 2.20 (1H, dd, J 13.0 and 5.1, 3-HA (maj 
fur)), 1.94 (1H, dd, J 13.0 and 11.8, 3-HB (maj fur)), 1.72-1.64 (2H, m, propyl 2-H2), 1.63-1.55 (2H, m, 
propyl 2-H2), 0.95-0.87 (6H, m, 2 × propyl 3-H3); HRMS Found M-H: 304.1399. C13H23NO7 
requires M-H, 304.1418.   
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The reaction produces two diastereoisomers at (4-S:4-R 75:25). The ratio of the 
diastereoisomers has been previously determined at 500 MHz 1H NMR, 8 forms of the sugar 
DPAH (including four furanose and four pyranose rings) are present.83,103 Full interpretation of 
the 8 products was not included but the spectra obtained were identical to the authentic 
sample.    
 
N-((3S,4S)-4,5-Dihydroxypent-1-en-3-yl)acetamide 58.81 
OH
OH
HN
O
 
D-Glyceraldehyde (0.6 g, 6.7 mmol), di-p-anisylmethylamine (1.62 g, 6.7 mmol) and vinyl 
boronic pinicol ester (2.05 g, 13.3 mmol) were stirred in a 4:1 ethanol-water (30 mL) solution 
for 72 h at 50 °C. TFA (2 mL) was then added and the solution stirred for a further 16 h. The 
solvent was removed in vacuo and the crude solid re-suspended in methanol (17 mL). Sodium 
bicarbonate (1.12 g, 13.4 mmol) and Ac2O (0.85 g, 8.4 mmol) was added and stirred for 1 h at 
room temperature. The solid was filtered and the filtrate reduced in vacuo. Crude product was 
purified via silica gel column chromatography (gradient elution CH2Cl2 → 90:10 CH2Cl2‒MeOH) 
to give the alkene 58 (0.34 g, 35 %) as a colourless glass, Rf: 0.14 (9:1, DCM‒MeOH), δH (500 
MHz; CD3OD) 5.97 (1H, ddd, J 17.2, 10.4 and 6.4, 2-H), 5.27 (1H, app. d, J 17.2, 1-HA), 5.23 (1H, 
app. d, J 10.4, 1-HB), 4.52 (1H, app. t, J 6.4, 3-H), 3.69-3.65 (1H, m, 4-H), 3.60 (1H, dd, J 11.3 and 
4.5, 5-HA), 3.54 (1H, dd, J 11.3 and 6.3, 5-HB), 2.03 (3H, s, acetyl Me); δC (75 MHz; CD3OD) 172.9 
(acetyl CO), 135.6 (2-C), 117.5 (1-C), 74.6 (4-C), 64.4 (5-C), 55.3 (3-C), 22.8 (acetyl Me); HRMS 
Found M+Na: 182.0788. C7H13NO3 requires M+Na, 182.0785.  
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(3S,5R)-Ethyl 5-((1R,2S)-1-acetamido-2,3-dihydroxypropyl)-2-tert-butylisoxazolidine-3-
carboxylate 36.81 
2
OH
OH
HN
O N
O
O
O
7
 
The alkene 58 (159 mg, 1.0 mmol) and the nitrone 38 (346 mg, 2.0 mmol) were stirred in 
dioxane (20 mL) at 30°C for 14 days. Reaction mixture was concentrated in vacuo and the 
crude product was purified via silica gel column chromatography (gradient elution: CH2Cl2 → 
90:10 CH2Cl2‒MeOH) to give the isoxazolidine 36 (99.6 mg, 30 %) as a colourless glass solid, Rf: 
0.15 (9:1, CH2Cl2‒MeOH); max/cm-1 (solid);  δH (500 MHz; CD3OD) 4.67 (1H, app. t, J 7.5, H-4), 
4.20 (2H, m, ethyl 1-H2), 3.99 (1H, app. t, J 8.3, H-2), 3.87 (1H, app. d, J 9.3, H-5), 3.64-3.60 (1H, 
m, H-6), 3.58 (1H, dd, J 12.1 and 2.12, H-7A), 3.47 (1H, dd, J 12.1 and 5.7, H-7B), 2.67 (1H, app. 
dt, J 12.3 and 7.5, H-3A), 2.17 (1H, app. dt, J 12.2 and 7.5, H-3B), 2.04 (3H, s, acetyl Me), 1.27 
(3H, q, J 7.1, ethyl 2-H3), 1.13 (9H, s, tbutyl 2-H3); δC (75 MHz; CD3OD) 174.12 (ethyl ester CO), 
174.02 (acetyl CO), 77.11 (4-C), 72.86 (6-C), 64.77 (7-C), 62.20 (ethyl 1-C), 61.91 (2-C), 60.99 
(tbutyl 1-C), 53.46 (5-C), 38.57, 25.67 (tbutyl 2-C), 22.51 (acetyl Me), 14.10 (ethyl 2-C); HRMS 
Found M+H: 333.2020. C15N28N2O6 requires M+H 333.2022.  
(The signals in NMR spectra are labelled according to the numbering system for N-
acetylneuraminic acid). 
 
5-Acetamido-2,4-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-carboxylic acid (ent-
ATOA).81 
O
CO2H
OH
HO
AcHN
OH
 
The Isoxazol 36 (77.6 mg, 0.23 mmol) was stirred in anhydrous MeONa (0.05 M, 10 mL) at 
room temperature for 12 h. The solution was then diluted with water (10 mL) and stirred for 
24 h. The mixture was purified directly with ion-exchange chromatography (Dowex 1X8- 
100resin, formate form) with gradient elution 0 → 2 M formic acid, providing the carboxylic 
acid ent-ATOA as a colourless glass solid (34.4 mg, 60%), [α]D
20: +23.7, max/cm-1 (solid) 3277, 
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2952, 2852 and 1682; δH (500 MHz; D2O) 4.01 (1H, ddd, J 11.6, 9.9 and 4.8, H-4), 3.83 (1H, ddd, 
J 10.6, 4.8 and 2.7, H-6), 3.75 (1H, app. d, J 10.6, H-5), 3.64 (1H, d, J 2.7, H-7A), 3.63 (1H, d, J 
4.8, H-7B), 2.22 (1H, dd, J 13.0 and 4.8, H-3eq), 2.07 (3H, s, acetyl 2-H3), 1.86 (1H, dd, J 13.0 and 
11.6, H-3ax); HRMS Found M-H: 248.0775. C9H15NO7 requires M-H 248.0776.  
 
N-((3S,4S,5R,6S)-4,5,6,7-Tetrahydroxyhept-1-en-3-yl)acetamide 65.81  
 
OH
OH
OH
OH
HN
O
 
L-Arabinose (1.0 g, 6.7 mmol), di-p-anisylmethylamine (1.62 g, 6.7 mmol) and vinyl boronic 
pinicol ester (2.05 g, 13.3 mmol) were stirred in a 4:1 ethanol‒water (30 mL) solution for 72 h 
at 50 °C. TFA (2 mL) was then added and the solution stirred for a further 16 h. The solvent was 
removed in vacuo and the crude solid re-suspended in methanol (17 mL). Sodium bicarbonate 
(1.12 g, 13.4 mmol) and Ac2O (0.85 g, 8.4 mmol) was added and stirred for 1 h at room 
temperature. The solid was filtered and the filtrate reduced in vacuo. The crude product was 
purified via silica gel column chromatography (gradient elution: CH2Cl2 → 90:10 CH2Cl2‒MeOH) 
to give the alkene 65 (0.74 g, 50 %) as a colourless glass, Rf: 0.06 (9:1, DCM‒MeOH); max/cm-1 
(solid) 3346.28, 2940.66 and 1672.96; δH (500 MHz; CD3OD) 6.06 (1H, ddd, J 16.8, 10.5 and 5.8, 
2-H), 5.23 (1H, dd, J 16.8 and 2.9, 1-HA), 5.18 (1H, dd, J 10.5 and 2.9, 1-HB), 4.56 (1H, app. t, J 
7.0, 3-H), 3.82 (1H, dd, J 11.0 and 3.5, 7-HA), 3.76 (1H, d, J 8.6, 4-H), 3.72 (1H, app. dd, J 8.5, 
3.5, 6-H), 3.66 (1H, dd, J 11.0 and 5.7, 7-HB), 3.55 (1H, d, J 7.4, 5-H), 2.0 (3H, S, acetyl 1-H); δC 
(75 MHz; CD3OD) 180.7 (acetyl CO), 136.9 (2-C), 116.8 (1-C), 72.4 (6-C), 72.0 (4-C), 71.2 (5-C), 
64.5 (7-C), 54.9 (3-C), 22.8 (acetyl Me); HRMS Found M+H: 220.1175. C9H17NO5 requires M+H, 
220.1179.  
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 (3S,5R)-Ethyl 5-((1R,2S,3R,4S)-1-acetamido-2,3,4,5-tetrahydroxypentyl)-2-tert-
butylisoxazolidine-3-carboxylate 66.81 
OH
OH
OH
OH
HN
O N
O
O
O
9
2
 
The alkene 65 (219 mg, 1.0 mmol) and the nitrone 38 (346 mg, 2.0 mmol) were stirred in 
dioxane (20 mL) at 30°C for 14 days. The reaction mixture was concentrated in vacuo and the 
crude product was purified via silica gel column chromatography (gradient elution: CH2Cl2 → 
90:10 CH2Cl2‒MeOH) to give the isoxazolidine 66 (215 mg, 55%) as a colourless glass, Rf: 0.18 
(9:1, DCM-MeOH); max/cm-1 (solid) 3399, 2924, 2851 and 1673; δH (500 MHz; CD3OD) 4.77 (1H, 
ddd, J 8.4, 7.0 and 1.4, 4-H), 4.29-4.18 (2H, m, ethyl 1-H2), 4.02 (1H, app. t, J 8.4, 2-H), 3.98 (1H, 
dd, J 10.2 and 1.4, 5-H), 3.91 (1H, app. d, J 10.2, 6-H), 3.92 (1H, dd, J 11.0 and 3.7, 9-HA), 3.77 
(1H, ddd, J 8.4, 5.3 and 3.7, 8-H), 3.69 (1H, dd, J 11.0 and 5.3, 9-HB), 3.49 (1H, app. d, J 8.4, 7-
H), 2.75 (1H, ddd, J 12.4, 8.2 and 7.0, 3-HA), 2.24 (1H, dt, J 12.4 and 8.4, 3-HB), 2.11 (3H, s, 
acetyl Me), 1.31 (3H, t, J 7.1, ethyl 2-H3), 1.18 (9H, s, tbutyl 2-H3); δC (75 MHz; CD3OD) 175.1 
(ethyl ester CO), 174.4 (acetyl CO), 77.3 (4-C), 72.3 (8-C), 71.5 (7-C), 70.6 (6-C), 65.0 (9-C), 62.5 
(ethyl 1-C), 62.2 (2-C), 61.2 (tbutyl 1-C), 39.0 (3-C), 26.0 (tbutyl 2-C), 22.9 (acetyl Me), 14.4 
(ethyl 2-C); HRMS Found M+H: 393.2243. C17H32N2O8 requires M+H 393.2231.  
(The signals in NMR spectra are labelled according to the numbering system for N-
acetylneuraminic acid). 
 
5-Acetamido-2,4-dihydroxy-6-((7S,8S)-7,8,9-trihydroxypropyl)tetrahydro-2H-pyran-2-
carboxylic acid (ent-NANA).81 
O
CO2H
OH
HO
AcHN
OH
HO
OH
 
The Isoxazol 55 (76 mg, 0.25 mmol) was stirred in anhydrous MeONa (0.05 M, 10 mL) at room 
temperature for 12 h. The solution was then diluted with water (10 mL) and stirred for 24 h. 
The mixture was purified directly with ion-exchange chromatography (Dowex 1X8- 100resin, 
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formate form) with gradient elution 0 → 2 M formic acid, providing the carboxylic acid ent-
NANA as a colourless glass solid (42.5 mg, 55%), [α]D
20: +18.3, max/cm-1 (solid) 3325.4, 
2931.48, 1732.42 and 1649.63; δH (500 MHz; D2O) 4.03-4.00 (1H, m, 4-H), 3.99 (1H, dd, J 10.3 
and 1.0, 6-H), 3.86 (1H, t, J 10.3, 5-H), 3.77 (1H, dd, J 11.8, 2.6, 9-HA), 3.68 (1H, ddd, J 9.0, 6.3 
and 2.6, 8-H), 3.55 (1H, dd, J 11.8 and 6.3, 9-HB), 3.49 (1H, dd, J 9.0 and 1.0, 7-H), 2.25 (1H, dd, 
J 13.1 and 4.9, 3-Heq), 1.98 (3H, s, acetyl 2-H3), 1.82 (1H, dd, J 13.1 and 11.7, 3-Hax); HRMS 
Found M-H: 308.0987. C11H19NO9 requires M-H 308.0982.  
 
(R)-2-(Furan-2-yl)-2-hydroxy-N,N-dipropylacetamide 85. 
 
Hoveyda–Grubbs II (7.4 mg, 0.01 mmol, 5 mol%) was added to a solution of dihydroxyamide 53  
(50 mg, 0.2 mmol) and acrolein (0.04 mL, 0.60 mmol) in MTBE (5 mL) and the resulting mixture 
was stirred at room temperature for 12 h. Tris(hydroxymethyl)phosphine (124 mg, 1.00 mmol) 
and NEt3 (0.14 mL, 1.00 mmol)  were added and stirred for 30 min, then silica (3 g) was added 
and stirred for 30 min. The slurry was filtered through Celite and concentrated to give a crude 
product. Purification by column chromatography (2:3 EtOAc–petrol) gave the furan 85 (20 mg, 
38 %) as a dark yellow oil; Rf: 0.3 (2:3 EtOAc–petrol);[α]D
20: −26.6 (c. 1.2 in MeOH); max/cm-1 
(film) 3390, 2966, 2936, 2877 and 1646; δH (500 MHz; CDCl3) 7.37 (1H, d, J 1.6, furanyl 5-H), 
6.35 (1H, dd, J 3.3 and 1.6, furanyl 4-H), 6.30 (1H, d, J 3.3, furanyl 3-H), 5.29 (1H, d, J 6.8, 2-H), 
4.68 (1H, d, J 6.8, OH), 3.49 (1H, ddd, J 15.1, 8.2 and 7.0, propyl 1-H), 3.23 (1H, ddd, J 15.1, 8.2 
and 6.8, propyl 1-H), 3.11 (1H, ddd, J 15.0, 10.1 and 6.2, propyl 1-H), 3.00 (1H, ddd, J 15.0, 10.1 
and 4.9, propyl 1-H), 1.65 - 1.54 (2H, m, 2 × propyl 2-H), 1.54-1.44 (1H, m, propyl 2-H), 1.25-
1.10 (1H, m, propyl 2-H), 0.89 (3H, t, J 7.4, propyl 3-H), 0.79 (3H, t, J 7.4, propyl 3-H); δC (75 
MHz; CDCl3) 170.0 (1-C), 152.9 (furanyl 2-C), 143.0 (furanyl 5-C), 111.1 (furanyl 4-C), 108.4 
(furanyl 3-C), 65.0 (2-C), 48.7 (propyl 1-H), 484 (propyl 1-H), 21.8 (propyl 2-H), 20.9 (propyl 2-
H), 11.7 (propyl 3-H), 11.4 (propyl 3-H); HRMS Found M+Na: 248.1267, C12H19NO3 requires 
M+Na, 248.1257. 
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 (4S,5S,E)-Methyl-6-(dipropylamino)-4,5-dihydroxy-6-oxohex-2-enoate 90. 
 
 
Grubbs II (49 mg, 0.06 mmol, 5 mol%), was added to a solution of dihydroxyamide 53 (250 mg, 
1.2 mmol) and methyl acrylate (0.3 mL, 3.5 mmol) in MTBE (7 mL), and the resulting mixture 
was heated at reflux for 5 days. The reaction mixture was cooled to room temperature, 
tris(hydroxymethyl)phosphine (600 mg, 25.8 mmol) and NEt3 (0.35 mL, 25.8 mmol) were 
added, stirred for 30 min, silica (6 g) added, stirred for 30 min, filtered through celite with 
EtOAc and concentrated under reduced pressure to give a crude product. Purification by 
column chromatography (2:3 EtOAc–petrol) give the methyl ester 90 (0.2 g, 63%,) as a 
colourless amorphous solid; m.p. 97–99 °C (petrol); Rf: 0.31 (1:2 EtOAc–petrol); [α]D
20: +5.9 (c. 
0.8 in MeOH); max/cm-1 (solid) 3500-3050, 2959 and 1716; δH (500 MHz; CDCl3) 6.90 (1H, dd, J 
15.5 and 4.6, 3-H), 6.13 (1H, dd, J 15.5 and 1.2, 2-H), 4.44 (1H, app. dd, J 7.5 and 4.6, 4-H), 4.41 
(1H, app. s, 5-H), 3.80 (1H, d, J 8.5, OH), 3.74 (3H, s, methyl ester Me), 3.55 (1H, m, propyl 1-H), 
3.45 (1H, d, J 4.5, OH), 3.34 (1H, m, propyl 1-H), 3.17 (1H, m, propyl 1-H), 3.09 (1H, m, propyl 1-
H), 1.59 (4H, m, 2 × propyl 2-H), 0.93 (3H, t, J 7.42, propyl 3-H), 0.90 (3H, t, J 7.42, propyl 3-H); 
δC (75 MHz; CDCl3) 171.2 (1-C), 166.8 (6-C), 145.6 (3-C), 123.0 (2-C), 73.0 (5-C), 70.5 (4-C), 52.1 
(methyl ester CO), 49.4 (propyl 1-C), 48.2 (propyl 1-C), 22.6 (propyl 2-C), 21.0 (propyl 2-C), 11.7 
(propyl 3-C), 11.5 (propyl 3-C); HRMS Found M+H: 274.1656. C13H23NO5 requires M+H, 
274.1649. 
 
(E)-Methyl-3-((4S,5S)-5-(dipropylcarbamoyl)-2,2-dimethyl-1,3-dioxolan-4-yl)acrylate 91. 
 
Methyl ester 90 (0.2 g, 0.7 mmol) and pTsOH (3.61 mg, 0.02 mmol) were added to a solution of 
1:1 2,2-dimethoxypropane‒acetone (10 mL) and stirred at room temperature for 12 h. 
Aqueous saturated NaHCO3 (5 mL) was added, extracted with EtOAc (3 × 5 mL), dried (MgSO4), 
filtered and concentrated under reduced pressure to give the  methyl ester 91 (0.16 g, 72%) as 
a colourless oil; Rf: 0.31 (1:3 EtOAc–petrol); [α]D
20: +12.3 (c. 0.5 in MeOH); max/cm-1 (solid) 
2937, 2966, 1728 and 1651; δH (500 MHz; CDCl3) 6.74 (1H, dd, J 15.6 and 6.4, 3-H), 6.04 (1H, 
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dd, J 15.6 and 1.2, 2-H), 4.95 (1H, d, J 7.5, 5-H), 4.89 (1H, ddd, J 7.5, 6.4 and 1.2, 4-H), 3.64 (3H, 
s, methyl ester Me), 3.35 (1H, dt, J 13.6 and 8.1, propyl 1-H), 3.12 (1H, ddd, J 15.5, 9.6 and 6.1, 
propyl 1-H), 3.03 (3H, ddd, J 15.5, 9.6 and 6.5, propyl 1-H), 2.96 (4H, dt, J 13.6 and 8.1, propyl 
1-H), 1.58 (3H, s, ipropyl MeA), 1.57-1.48 (2H, m, propyl 2-H), 1.41 (2H, app. sextet J 7.6 propyl 
2-H), 1.34 (3H, s, ipropyl MeB), 0.84 (3H, t, J 7.4, propyl 3-H), 0.79 (3H, t, J 7.4, propyl 3-H); δC 
(75 MHz; CDCl3) 166.7 (C-6), 165.8 (C-1), 142.5 (C-3), 123.4 (C-2), 111.3 (ipropyl 2-C), 76.7 (4-C), 
76.3 (5-C), 51.6 (methyl ester Me), 48.9 (propyl 1-C), 48.2 (propyl 1-C), 26.7 (MeB), 25.3 (MeA), 
22.2 (propyl 2-C), 20.4 (propyl 2-C), 11.1 (propyl 3-C), 11.1 (propyl 3-C); HRMS Found M+H: 
314.1911. C16H27NO5 requires M+H, 314.1967.  
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Appendix I. Mass spectrometric data 
for the chemically modified proteins 
 
Below are the multiple mass-charge state spectra of the SaNAL variants used for kinetic 
measurements. These spectra were obtained through the methods shown in section 4.1.19. 
The multiple mass-charge state spectra (primary data) are shown and the 31+ peak is 
highlighted in each spectrum. This is related to the mass of the protein through the mass-to-
charge ratio, m/z.84 The primary data was routeinly deconvoluted by Dr. James Ault (University 
of Leeds) using MassLynx software to obtain the molecular mass of the protein. These samples 
have been taken after gel filtration. In some cases, adducts from side reactions were observed. 
This was potentially caused by over alkylation by the dibromide compound 28.104  Despite this, 
peaks were seen for the correct size of modified proteins and these samples were used for 
kinetic characterisation.  
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Appendix II. Supplementary kinetic 
data 
 
In order to assess the validity of the kinetic assay, several control measurements were 
performed, in which the decrease in concentration of NADH was observed over a period of 30 
minutes. These measurements can be seen in Table 5. Each measurement was performed with 
one component of the assay missing, i.e. no protein was used when measuring each of the 
substrates effect on the assay; no substrate was used when measuring the effect of the 
protein on the assay. The background decrease in NADH concentration is therefore shown for 
each component in the assay.  The substrate concentrations used in these measurements are 
the highest concentrations used when performing the kinetic assays. The enzyme 
concentration used is also typical of my standard assay at 0.1 mg/ml. From the changes in 
absorbance observed for each of the control reactions (Table 5) it could be inferred that no 
component would interfere with the kinetic assay measurements.  
  
Table 5 | Background reactions performed to assess the reliability of the coupled enzyme 
assay. 
  
50mM Tris 
(µL) 
LDH 
(µL) 
20mM 
NADH 
(µL) 
100mM 
subs (µL) 
E192-
AMCEC 
(µL) Δ A340/30min 
N-acetylneuraminic 
acid 788 2 10 200 0 0.0001 
DPAH 938 2 10 50 0 0.0011 
ATOA 688 2 10 300 0 0.0019 
ent-ATOA 938 2 10 50 0 0.0010 
ent-NANA 983 2 10 5 0 0.0018 
enz 977.1 2 10 0 10.9 0.0001 
no LDH-SA 779.1 0 10 200 10.9 0.0017 
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Graphs of specific activity used to determine kinetic parameters of SaNAL 
variants: 
 
In this part of the appendix you will find the activity plots for all variants of SaNAL with the 
substrates N-acetylneuraminic acid, DPAH and ATOA.  
 
Activity plots of the SaNAL variants with the N-acetylneuraminic acid as a 
substrate: 
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Activity plots of the SaNAL variants with the N-acetylneuraminic acid analogue 
DPAH as a substrate: 
 
 
126 
 
 
 
 
127 
 
Activity plots of the SaNAL variants with the N-acetylneuraminic acid analogue 
ATOA as a substrate: 
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Appendix III. supplementary future 
work results and discussion 
 
As discussed in section 3.5, the α,β-unsaturated carbonyl compounds 73, 74 and 75 could 
potentially act as inhibitors of SaNAL variants. Work towards the synthesis of the α,β-
unsaturated carbonyl compounds 74 and 75 had begun. Compounds 73, 74 and 75 (Figure 47) 
are to be synthesised as possible E192N aldolase inhibitors. 
 
 
Figure 47 | Three α,β-unsaturated analogues of DPAH to be synthesised.  
 
An obvious starting point for the synthesis of the compounds seen in (Scheme 36) would be 
the cross metathesis of the compound 53 with an alkene containing a carbonyl moiety such as 
compound 79. This route was chosen as the synthesis of compound 53 had already been 
established. 
 
Scheme 36| proposed cross metathesis of compound 53 to yield compound 78. 
Compound 78 would contain functionality which would hopefully (with little further chemical 
modification) lead to the synthesis of the compounds 73, 74 and 75. Therefore several cross 
metathesis reactions were attempted with the compound 53 and the alkenes 80, 81, 82 and 83 
(Figure 48).  
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Figure 48 | Alkenes used in cross metathesis reactions with compound 53. 
 
The metathesis reaction between compound 53 and 82, was expected to give the compound 
84, but surprisingly gave the furan 85, in 38% yield (Scheme 37).  
 
 
Scheme 37| cross metathesis reaction with acrolein 82 and the alkene 53. This reaction gave 
the furan 85. 
 
An Achmatowicz reaction could possibly be performed to open the furan ring and provide the 
α,β-unsaturated carbonyl 75 (Scheme 38).  
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Scheme 38| Proposed Achmatowicz reaction leading to the α,β-unsaturated carbonyl 
compound 75. 
 
An alternate route proposed for the synthesis of the α,β-unsaturated carbonyl compound 74 
can be seen in Scheme 39. The route begins with the cross metathesis with the compound 53 
and methyl acrylate 80 which gave the methyl ester 90 in 63% yield. After cross metathesis, 
the diol of compound 90 was protected to give the acetonide 91 in 72% yield. After this an 
oxidation, reduction and deprotection may lead to the compound 74. A preliminary reduction 
of the methyl ester 91 with DIBAL-H has yielded a low quantity of the alcohol 92 (observed by 
500 MHz 1H NMR). With optimisation of this reaction, followed by oxidation and deprotection, 
74 may result.  
132 
 
 
Scheme 39 | Proposed synthesis of the α,β-unsaturated carbonyl compounds 74. 
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